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Non-healing bone defects have a significant socioeconomic impact in the U.S. 
with approximately 600,000 bone grafting procedures performed annually.  Autografts 
and allografts are clinically the most common treatments; however, autologous donor 
bone is in limited supply, and allografts often have poor mechanical properties.  
Therefore, tissue engineering and regenerative medicine strategies, which employ the use 
of cells or growth factors to heal bone, are being developed to address issues with clinical 
bone grafting.  However, the need for an abundant mineralizing cell source limits the 
progress of these therapies. The overall objective of this work was to develop bone tissue 
engineering strategies that enhance healing of orthotopic defects by targeting specific 
osteogenic cell signaling pathways.  The general approach included the investigation of 
two different tissue engineering strategies, which both focused on directed osteoblastic 
differentiation to promote bone formation. 
In the first cell-based strategy, we hypothesized that constitutive overexpression 
of the osteoblast-specific transcription factor, Runx2, in bone marrow stromal cells 
(BMSCs) would promote orthotopic bone formation in vivo.  We tested this hypothesis 
by delivering Runx2-modified BMSCs on synthetic scaffolds to critically-sized defects in 
rats.  We found that Runx2-modified BMSCs significantly increased orthotopic bone 
formation compared to empty defects, cell-free scaffolds and unmodified BMSCs.  This 
gene therapy approach to bone regeneration provides a mineralizing cell source which 
has clinical relevance. 
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In the second biomaterial-based strategy, we hypothesized that incorporation of 
the collagen-mimetic peptide, GFOGER, into synthetic bone scaffolds would promote 
orthotopic bone formation in vivo without the use of cells or growth factors.  We tested 
this hypothesis by passively adsorbing GFOGER onto poly-caprolactone (PCL) scaffolds 
and implanting them into critically-sized orthotopic defects in rats.  We found that 
GFOGER-coated scaffolds significantly increased bone formation compared to uncoated 
scaffolds in a dose dependent manner.  Development of this cell-free strategy for bone 
tissue engineering provides an inexpensive therapeutic alternative to clinical bone defect 
healing, which avoids issues of immune response from implanted materials and could be 
implemented in a point of care application. 
 Both of the strategies developed in this work take advantage of specific 
osteoblastic signaling pathways involved in bone healing.  Further development of these 
tissue engineering strategies for bone regeneration will provide clinically-relevant 
treatment options for healing large bone defects in humans by employing well-controlled 











Non-healing bone defects have a significant socioeconomic impact in the U.S. 
with approximately 600,000 bone grafting procedures performed annually (Bucholz 
2002).  Current clinical treatment of large bone defects employs the use of autografts and 
allografts; however, autografts can cause donor site morbidity and pain and must be taken 
from a limited supply of donor bone, while allografts may have poor mechanical 
properties and present a risk of disease transmission (Meyer et al. 2004; Hutmacher and 
García 2005).  As an alternative approach for bone repair, tissue engineering and 
regenerative medicine strategies are being developed to address the problems associated 
with current bone grafting procedures.  Many of these strategies make use of a 
mineralizing cell source that is delivered to a defect site to promote bone formation.  
However, the identification of the ideal cell source for bone tissue engineering remains to 
be uncovered.  The overall objective of this work was to develop bone tissue engineering 
strategies that enhance healing of orthotopic defects by targeting specific osteogenic cell 
signaling pathways.  These specific targeting strategies, which exert control over donor 
and host cell signaling pathways, address the current limitations of cell sourcing for bone 
tissue engineering by increasing the osteogenic capacity of donor cells or by promoting 
host osteogenesis in the absence of donor cells.  These strategies improve upon existing 
bone tissue engineering strategies and present valuable alternatives for clinical healing of 
large bone defects. 
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 Bone marrow stromal cells (BMSCs) are a heterogeneous population of 
multipotent cells, easily obtained from the bone marrow, that have the ability to 
differentiate towards the osteogenic, chondrogenic or adipogenic lineages (Pittenger et al. 
1999).  However, the growth rate and osteoblastic differentiation potential of BMSCs is 
negatively affected by ex vivo manipulation and expansion of the cells (Derubeis and 
Cancedda 2004).  Runx2 is an osteoblast-specific transcription factor that upregulates 
osteoblast-specific genes and promotes osteoblastic differentiation of BMSCs both in 
vitro and in vivo (Byers and García 2004).  For this work, we hypothesized that the 
delivery of BMSCs, genetically modified to overexpress Runx2, into critically-sized 
orthotopic defects would facilitate increased healing of the defects compared to delivery 
of unmodified BMSCs. 
 Synthetic polymeric scaffolds have been used to deliver cells and growth factors 
to critically-sized orthotopic defects to facilitate defect healing (Rohner et al. 2003; 
Schantz et al. 2003; Oest et al. 2007).  However, polymeric scaffolds alone are not 
sufficient for repair of critically-sized defects.  Recently, the use of biomimetic strategies 
which attempt to recapitulate the environment of the bone ECM have been used to 
promote osseointegration and bone formation in vivo (Hubbell 2003).  In particular, 
surface modification of titanium implants with the synthetic peptide GFOGER, derived 
from collagen I, has been shown to significantly increase osseointegration and implant 
fixation in vivo to levels greater than that of unmodified titanium implants or implants 
coated with full length collagen I (Reyes et al. 2007).  Furthermore, GFOGER signaling 
occurs via binding of the α2β1 integrin receptor and upregulation of Runx2 (Xiao et al. 
1998).  Therefore, we further hypothesized that surface modification of synthetic polymer 
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scaffolds with the peptide, GFOGER, would significantly improve healing of critically-
sized orthotopic defects compared to unmodified scaffolds without the use of cells or 
growth factors.  These hypotheses were tested via the following three specific aims: 
 
1. To examine the Runx2-induced osteogenic potential of BMSCs from an inbred rat 
strain compared to that of BMSCs from a previously established outbred rat strain. 
 
 Genetic modification of BMSCs with Runx2 upregulates the expression of 
osteoblast-specific genes and subsequently increases mineralization in BMSCs isolated 
from Wistar rats, an outbred rat strain (Byers and García 2004).  To proceed with in vivo 
studies, we were interested in using inbred rats to address concerns with immune 
rejection of implanted cells.  However, strain differences in rats affect a number of 
physiological processes, such as skeletal development and ectopic bone formation 
(DeMoss and Wright 1998; Li et al. 2003).  Our hypothesis for this aim was that the 
strain of rat from which BMSCs were isolated would affect the in vitro osteogenic 
potential of BMSCs but that Runx2 modification would remain effective in promoting 
osteoblastic differentiation.  We tested this hypothesis by harvesting BMSCs from both 
Lewis and Wistar rats, an inbred and outbred strain, respectively.  Osteogenic potential of 
all cells was quantified via alkaline phosphatase activity and in vitro mineralization of 2D 
surfaces.  Furthermore, the effect of Runx2 modification and passage number on all cell 




2. To evaluate bone regeneration and mechanical strength induced by Runx2-
engineered BMSCs in critically-sized segmental defects. 
 
 The implantation of BMSCs, engineered to overexpress Runx2, causes significant 
healing of critically-sized rat calvarial defects compared to treatment with unmodified 
BMSCs (Byers et al. 2006).  Although these results are promising, segmental defects 
provide a more rigorous test bed than calvarial defects for bone tissue engineering by 
eliminating the host response from the cranial periosteum and underlying dura mater 
(Aalami et al. 2003).  For this aim, we hypothesized that delivery of Runx2 modified 
BMSCs to critically-sized segmental defects would significantly increase bone formation 
and mechanical strength of defects compared to treatment with unmodified BMSCs.  To 
test this hypothesis, we seeded BMSCs, retrovirally-transduced to overexpress Runx2, 
onto PCL scaffolds and implanted the cell/scaffold constructs into critically-sized defects 
in rat femurs.  Control groups included empty defects, cell-free scaffolds, and scaffolds 
seeded with unmodified BMSCs or empty-vector-modified BMSCs.  Bone volume in 
defects was quantified at 4, 8 and 12 weeks via microCT.  Postmortem analysis of 
explanted samples included histology, FTIR, and mechanical testing. 
 
3. To evaluate the extent of bone regeneration and mechanical strength induced by 
GFOGER-modified PCL scaffolds in critically-sized orthotopic defects. 
 
 Although the synthetic polymer, PCL, can be used as a biomaterial for bone tissue 
engineering scaffolds (Zein et al. 2002; Byers et al. 2006), the surface hydrophobicity of 
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these scaffolds causes non-specific protein adsorption, resulting in a non-specific cell 
signaling response.  For this aim, we hypothesized that incorporation of the bioadhesive 
molecule, GFOGER, into synthetic bone scaffolds would promote healing of critically-
sized bone defects without the use of cells or growth factors.  We tested this hypothesis 
by passively adsorbing GFOGER onto PCL scaffolds and implanting GFOGER-coated 
scaffolds into critically-sized defects in rat femurs.  Control groups included empty 
defects and uncoated PCL scaffolds.  Bone volume in defects was quantified at 4, 8 and 
12 weeks via microCT.  Postmortem analysis of explanted samples included histology 
and mechanical testing. 
   
 This work is innovative because it uses novel genetic and extracellular cues for 
osteoblastic differentiation and mineralization to address the issue of cell sourcing, a 
common problem for tissue engineered constructs.  By engineering BMSCs to 
overexpress Runx2, issues with donor variation and ex vivo manipulation of BMSCs are 
abrogated.  Furthermore, surface modification of synthetic scaffolds with GFOGER, 
confers biofunctionality to otherwise non-bioactive substrates and promotes specific 
signaling to host cells, thereby eliminating the need for donor cells. We expect that 
development of these tissue engineering approaches to bone regeneration will provide a 
clinically-relevant strategy for the treatment of bone defects by eliminating the need for 
donor bone and employing well-controlled signals for bone formation. 
References 
Aalami OO, Nacamuli RP and Longaker MT (2003). "Roles of periosteum, dura, and 
adjacent bone on healing of cranial osteonecrosis - Discussion." Journal of 
Craniofacial Surgery 14(3): 380-382. 
 
 6 
Bucholz RW (2002). "Nonallograft osteoconductive bone graft substitutes." Clinical 
Orthopaedics and Related Research 395: 44-52. 
Byers B, Guldberg R, Hutmacher D and García A (2006). "Effects of Runx2 genetic 
engineering and in vitro maturation of tissue-engineered constructs on the repair 
of critical size bone defects." Journal of Biomedical Materials Research Part A 
76A(3): 646-655. 
Byers BA and García AJ (2004). "Exogenous Runx2 expression enhances in vitro 
osteoblastic differentiation and mineralization in primary bone marrow stromal 
cells." Tissue Engineering 10(11/12): 1623-1632. 
Byers BA, Guldberg RE, Hutmacher DW and García AJ (2006). "Effects of Runx2 
genetic engineering and in vitro maturation of tissue-engineered constructs on the 
repair of critical size bone defects." J Biomed Mater Res A 76(3): 646-55. 
Derubeis AR and Cancedda R (2004). "Bone marrow stromal cells (BMSCs) in bone 
engineering: limitations and recent advances." Ann Biomed Eng 32(1): 160-5. 
Hubbell JA (2003). "Materials as morphogenetic guides in tissue engineering." Curr Opin 
Biotechnol 14(5): 551-8. 
Hutmacher DW and García AJ (2005). "Scaffold-based bone engineering by using 
genetically modified cells." Gene 347: 1-10. 
Meyer U, Joos U and Wiesmann HP (2004). "Biological and biophysical principles in 
extracorporal bone tissue engineering:  Part III." International Journal of Oral and 
Maxillofacial Surgery 33(7): 635-641. 
Oest ME, Dupont KM, Kong HJ, Mooney DJ and Guldberg RE (2007). "Quantitative 
assessment of scaffold and growth factor-mediated repair of critically sized bone 
defects." J Orthop Res 25(7): 941-50. 
Rohner D, Hutmacher DW, Cheng TK, Oberholzer M and Hammer B (2003). "In vivo 
efficacy of bone-marrow-coated polycaprolactone scaffolds for the reconstruction 




Schantz JT, Hutmacher DW, Lam CX, Brinkmann M, Wong KM, Lim TC, Chou N, 
Guldberg RE and Teoh SH (2003). "Repair of calvarial defects with customised 
tissue-engineered bone grafts II. Evaluation of cellular efficiency and efficacy in 
vivo." Tissue Eng 9 Suppl 1: S127-39. 
Zein I, Hutmacher DW, Tan KC and Teoh SH (2002). "Fused deposition modeling of 











Bone Structure and Repair  
Structure 
 Bone is a highly organized tissue that can be categorized into several structural 
types.  In particular, long bones, the focus of this dissertation, are composed of a cortical 
shaft with trabecular bone on either end.  Cortical bone is dense and comprises about 
80% of the human skeleton, while trabecular bone consists of an array of plates and rods 
that form a lattice-like structure (Liebschner 2004).  In the present work, where bone 
tissue engineering strategies are evaluated in segmental defects created in long bones, 
structural and functional recapitulation of cortical bone is the goal. 
At the microstructural level, normal adult human cortical bone is arranged into 
osteons and lamellar sheets.  Osteons are formed when planar sheets of mineralized 
collagen fibers called lamellae form concentric rings around an open channel.  Lamellae 
can also form parallel arrays called circumferential lamellar bone (Rho et al. 1998).  
Although lamellar bone is common to all vertebrate animals, generally only large animals 
have osteonal lamellar organization, whereas the skeletons of small animals are primarily 
arranged in lamellar plates.  The particular arrangement of lamellae within cortical bone 
lends structural support to the tissue, creating a niche for the characterization of structure 
function relationships in bone.  However, the complexity of bone tissue and the difficulty 
in measuring the mechanical properties of bone on a molecular level make this task 
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challenging.  To date, the structure function relationship in lamellar bone has not been 
fully elucidated (Weiner et al. 1999). 
Bone repair 
 Bone is one of the few tissues with the unique ability to regenerate after injury 
with full restoration of function to the injured site.  The process of bone repair is highly 
complex and involves the coordination of many different cell and tissue types to produce 
the desired response.  There are four main tissue types that contribute to fracture healing 
in bone (Figure 2.1), which participate in both endochondral and intramembranous bone 
formation (Einhorn 1998).  The general process involves hematoma formation and 
inflammation, leading to development of a soft tissue callus surrounding the defect site, 
which is eventually mineralized and remodeled into mature lamellar bone (Einhorn 1998; 
Duvall et al. 2007).  This process occurs naturally after injury to bone tissue; however, 
successful healing is only realized in fractures that do not result in substantial bone loss.  
Defects resulting in non-union of the injured tissue require clinical therapy for healing. 
 
Figure 2.1.  The tissue types that contribute to fracture healing in bone.  




Clinical Repair of Bone Defects 
Although fracture repair of long bones occurs successfully with little to no 
surgical intervention, non-unions, in which a large portion of the bone is injured or must 
be resected, will remain as open defects until treated.  The gold standard for clinical 
treatment of non-unions remains as the autograft, followed closely in number of 
treatments by allograft.  However, recent use of bone morphogenetic proteins (BMPs) to 
treat large bone defects in humans is a newly emerging standard of care despite its high 
cost.  These therapies, along with other current clinical treatments, will be discussed. 
Autografts and Allografts 
 In 2002, it was estimated that 600,000 bone grafting procedures were performed 
annually in the U.S., consisting of spinal fusions, general orthopaedic procedures, and 
synthetic bone grafts (Bucholz 2002).  In 2004, approximately $5 billion was invested in 
more than 1,000,000 procedures involving bone grafting, bone excision and fracture 
repair (Kretlow and Mikos 2007).  Autografts remain the gold standard for orthopaedic 
replacement procedures, including cases of non-union in long bones or 
craniomaxillofacial procedures.  The graft material is most commonly taken from the 
iliac crest providing both an osteoconductive matrix for bone cell adhesion and an 
osteoinductive growth factor environment promoting osteoblastic differentiation (De 
Long et al. 2007).  Furthermore, because bone is transferred from one site in the patient 
to another site in the same patient, autografts elicit no immunogenic host response.  
However, the repair of large bone defects in humans remains a significant clinical 
problem despite successful healing of defects treated with autografts.  Although 
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autografts contain the appropriate cues for osteogenesis and elicit no immunogenicity, 
donor site morbidity and pain affect as many as 30% of patients who have undergone a 
bone harvest from the iliac crest (Gottfried and Dailey 2008; Rawashdeh and Telfah 
2008).   
 Approximately 1/3 of all bone grafts in North America are allografts, where 
cadaveric bone is taken from an unrelated donor and frozen until use (De Long et al. 
2007).  Allografts are widely used to address the issue of donor tissue availability for 
autografts; however, they present a different set of problems.  Because bone is transferred 
from donor to patient, graft material may be infected or cause a significant 
immunological host response.  The process of freezing allografts has reduced immune 
issues, but major infections causing graft failure are still reported to occur in about 8% of 
patients.  Furthermore, extensive processing of allografts causes poor mechanical 
properties and increased rates of resorption and fracture, leading to graft failure rates as 
high as 50% (Sorger et al. 2001; Mankin et al. 2005) and leading many researchers to 
investigate alternative strategies.  
Bone Morphogenetic Proteins 
 The first well documented study of bone formation by osteoinduction was 
described by Marshall Urist in 1965 by the implantation of demineralized bone matrices 
into ectopic sites in rabbits and rodents (Urist 1965).  From this experiment came the 
discovery and characterization of bone morphogenetic proteins (BMPs), soluble growth 
factors that work through Smad-dependent signaling pathways to promote osteoblastic 
diffentiation (Derynck and Zhang 2003).  More than 15 individual BMPs have now been 
identified and several studies have shown that BMP-2 and BMP-7 promote healing of 
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critically-sized bone defects in both small and large animals (Yasko et al. 1992; Cook et 
al. 1994; Cook et al. 1994; Cook et al. 1995) and in humans (Govender et al. 2002).  
Additionally, BMP-2 and BMP-7 are currently approved for human use in the United 
States and Europe (Boden 2005; Bishop and Einhorn 2007; Vaibhav et al. 2007), making 
treatment with BMPs a newly emerging standard of care that may soon replace autografts 
as the gold standard of treatment. 
 Although the use of BMPs in clinical repair of bone defects has demonstrated 
success, several factors contribute to the continued search for bone tissue engineering 
alternatives.  First, the residence time of BMP in a defect site following localized delivery 
directly affects its osteogenic potential.  As a soluble factor, diffusion of BMP away from 
the delivery site decreases the amount of bone formed in an implant (Uludag et al. 2000).  
Efforts are being made to increase BMP residence time at the defect site (Yamachika et 
al. 2009).  Second, the dosage of BMPs required to stimulate bone formation in large 
bone defects in humans far exceeds the successful working dosage described in 
preclinical trials.  In fact, one vial of BMP-7 contains as much BMP-7 as is found in two 
entire human skeletons.  Thus, production of enough recombinant protein for one vial of 
BMP for human use is a very costly procedure (Alt and Heissel 2006; Bishop and 
Einhorn 2007; Cancedda et al. 2007). 
Synthetic Bone Grafts:  Calcium phosphates 
  Despite the increasing need for more suitable bone replacement therapies, 
synthetic bone graft substitutes make up only about 10% of all clinical bone grafting 
procedures (Bucholz 2002).  Most of FDA approved synthetic grafts are composed of 
hydroxyapatite or other ceramic composites which possess inherent osteoconductive 
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properties.  Pro-Osteon, the first bone graft substitute to gain FDA approval, is an 
interporous hydroxyapatite material derived from coral with a natural architecture similar 
to that of native human cancellous bone.  Blocks of the material can be milled to fit the 
shape and size of a defect, and bone forms readily within and around the implant, making 
it an effective filler.  Due to the brittle nature of hydroxyapatite, Pro-Osteon is restricted 
to use in non-loaded defects, or defects in which internal rigid fixation is applied.  For the 
FDA-approved product, Vitoss, small beta-tricalcium phosphate particles are formed into 
a 90% porous matrix.  The resulting scaffold has both microscale and macroscale 
porosity, aiding in nutrient diffusion through the scaffold.  Furthermore, this material has 
a resorption rate similar to that of native bone, which is conducive to eventual remodeling 
of treated defects.  Collagraft is a composite scaffold consisting of porous calcium 
phosphate granules contained with a matrix of bovine-derived collagen fibrils.  Before 
implantation, autogenous bone marrow is added to the scaffold.  Collagraft has 
demonstrated similar results to autograft in clinical trials.  These products join an ever 
growing list of commercially available calcium phosphate grafts (De Long et al. 2007). 
Autologous bone marrow progenitor cells 
 Although not yet common practice, the use of autogenous bone marrow derived 
cells for clinical treatment of non-unions has recently gained attention.  The first clinical 
report of the use autologous bone marrow progenitor cells for treatment of large bone 
defects in humans was in 2001 by Quarto and colleagues (Quarto et al. 2001).  Three 
patients with substantial defects in their long bones (4 cm defect in the tibia, 4 cm ulna, 
and 7 cm humerus) underwent bone marrow harvests from the iliac crest, and the cells 
were cultured ex vivo according to previous methods (Martin et al. 1997).  
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Hydroxyapatite scaffolds were modified to fit the size and shape of each defect, and cells 
were seeded onto scaffolds prior to implantation.  Six months to one year after surgery, 
external fixation was removed, and all patients had recovered normal limb function.  In a 
6-7 year follow-up study, which included a fourth patient with a 6cm defect in the ulna, 
all patients demonstrated complete bone implant integration as determined by 
radiography and CT analysis (Marcacci et al. 2007).  The success of these studies 
warrants further investigation of the use of autologous BMSCs in treating clinical non-
unions.  However, no subsequent reports have been made. 
Bone Tissue Engineering Strategies 
As an alternative approach to current clinical bone repair, tissue engineering and 
regenerative medicine strategies are being developed to address the problems associated 
with current bone grafting procedures (Hutmacher and García 2005; Awad et al. 2007; 
Cancedda et al. 2007; Kimelman et al. 2007).  These strategies involve the development 
of tissue-engineered cell/scaffold constructs, whereby cells on synthetic scaffolds are 
implanted into a defect site, directly associate with native host tissue, and eventually 
restore natural tissue structure and function (Langer and Vacanti 1993).  For bone 
regeneration, tissue engineering strategies focus on the isolation and control of a 
mineralizing cell source as well as the development of scaffolds with relevant mechanical 
properties and appropriate pore volumes (Guillot et al. 2007; Kretlow and Mikos 2007). 
Cell types 
An appropriate cell source for bone tissue engineering must address several 
criteria.  First, cells must be available in abundant quantities and non-invasively obtained 
from the patient.  Further, transplantation of the cells should be safe and pose no risk of 
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disease transmission to the patient (Gimble et al. 2007).  Many cell types for bone tissue 
engineering are currently being investigated, the most common of which is bone marrow 
stromal cells. 
Bone marrow stromal cells (BMSCs) are easily obtained from bone marrow 
aspirates and have the ability to differentiate down several mesodermal tissue lineages 
(Pittenger et al. 1999).  BMSCs provide an appropriate autologous cell source for human 
bone tissue regeneration (Bruder et al. 1994; Quarto et al. 2001; Derubeis and Cancedda 
2004).  They can be extracted in large quanties from the iliac crest with minimal donor 
site morbidity (De Long et al. 2007), can be expanded in culture, and respond to intra- 
and extracellular cues for differentiation (Majors et al. 1997). BMSCs have the capability 
of differentiating into osteoblasts, among other cell types of the mesodermal lineage, and 
they mineralize constructs both in vitro and in vivo (Goshima et al. 1991; Ishaug et al. 
1997; Krebsbach et al. 1997; Cartmell et al. 2004).  BMSCs also enhance bone healing in 
critically-sized orthotopic defects in rodents and large animals compared to treatment 
with a scaffold alone (Werntz et al. 1996; Bruder et al. 1998; Kon et al. 2000; Petite et al. 
2000).  Recent evidence suggests that BMSCs may also be used as an allogeneic cell 
source due to the secretion of immunosuppressive trophic factors (Caplan 2007), making 
these cells a good source for “off the shelf” tissue engineering strategies. 
Although BMSCs are an appropriate cell source for bone tissue engineering, 
extensive in vitro culture causes morphology changes, reduction in proliferation rate, and 
reduced osteogenic differentiation ability (Banfi et al. 2000; Derubeis and Cancedda 
2004; Yeon Lim et al. 2006). Furthermore, the mineralization potential and proliferation 
rate of BMSCs varies widely with individual donors and is significantly affected by 
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donor age (Phinney et al. 1999; Mendes et al. 2002; Kretlow et al. 2008).  These 
variations in BMSC function imply that the treatment of large bone defects with 
autologous BMSCs may not produce effective results for all patients.  Alternative cell 
types with osteogenic potential for bone tissue engineering are currently being explored.  
Initial work with adipose-derived stem cells and amniotic fluid stem cells have shown 
promising potential for the ability of these cells to differentiate down an osteoblastic 
lineage (Muschler et al. 2004; Gimble et al. 2007; Ilancheran et al. 2007).  However, the 
search for the ideal cell source for bone tissue engineering continues. 
Gene therapy 
To improve the osteogenic potential of cells used for bone tissue engineering, 
gene therapy strategies, which force overexpression or silencing of a target gene in a 
given cell population have been developed.  Genetic modification of cells can be 
achieved through a variety of carriers, may promote stable or transient gene expression, 
and can be applied in vivo or ex vivo (Gersbach et al. 2007).  Extensive work has focused 
on the delivery of BMPs to promote osteoblastic differentiation of cells delivered to bone 
defect sites (Hanada et al. 1997; Gazit et al. 1999; Huang et al. 2005; Edgar et al. 2007; 
Hsu et al. 2007). Ex vivo gene transfer of BMP-2 to BMSCs accelerates the time course 
of bone defect healing compared to treatment with unmodified BMSCs (Lieberman et al. 
1999; Baltzer et al. 2000; Blum et al. 2003). 
In addition to BMP, gene therapy strategies targeting osteoblast-specific 
transcription factors, such as Runx2 and, more recently, osterix, have been used to 
increase the bone forming potential of the target cell population.  Runx2/Cbfa1 and 
osterix are transcription factors that upregulate the expression of many osteoblast-specific 
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genes, such as osteopontin, osteocalcin, bone sialoprotein and collagen I (Ducy et al. 
1997; Nakashima et al. 2002).  Osterix acts downstream of Runx2, such that forced 
overexpression of osterix in BMSCs does not upregulate Runx2, and Runx2 null mice do 
not express osterix (Nakashima et al. 2002; Tu et al. 2006).  The role of Runx2 in 
osteoblastic differentiation has been demonstrated both in vitro and in vivo, in human and 
rodent systems (Otto et al. 1997; Shui et al. 2003).  Furthermore, retroviral delivery of 
Runx2 to rodent BMSCs promotes osteoblastic differentiation of these cells even after 
multiple passages in vitro (Byers and García 2004; Byers et al. 2006). 
Skeletal abnormalities have been observed in the absence of Runx2 function.  For 
example, transgenic mice expressing a dominant negative form of Runx2 develop 
abnormally even after normal embryonic development (Ducy et al. 1999).  Homozygous 
deletion of Runx2 in mice results in embryonic lethality and a complete lack of bone 
formation (Komori et al. 1997; Otto et al. 1997), while heterozygous Runx2 mutant mice 
show impaired mineralization and bone formation compared to wild-types (Otto et al. 
1997).  Finally, the human disease, cleidocranial dysplasia, occurs as a result of genetic 
mutations in Runx2 (Lee et al. 1997; Mundlos et al. 1997; Zhang et al. 2000). 
Forced overexpression of Runx2, therefore, has been used to promote 
osteogenesis in vitro and in vivo in BMSCs (Byers and García 2004), and recent use of 
osterix has produced similar results (Tu et al. 2006).  Interestingly, Runx2 overexpression 
also causes osteoblastic differentiation in non-osteoblastic cell lineages, such as 
myoblasts and dermal fibroblasts (Gersbach et al. 2004; Gersbach et al. 2004; Phillips et 
al. 2007), demonstrating the nature of Runx2 as a molecular switch in osteoblast biology 
(Ducy 2000).  Recently, several studies have shown that Runx2-modified or osterix-
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modified BMSCs delivered to cranial defects in rodents significantly increase defect 
healing compared to unmodified BMSCs (Zheng et al. 2004; Zhao et al. 2005; Byers et 
al. 2006; Tu et al. 2007), pointing to gene therapy strategies which incorporate 
transcription factors as a viable alternative to BMP gene delivery. 
Synthetic and Biomimetic Scaffolds 
Delivery of a therapeutic load of genetically-modified or unmodified BMSCs to a 
critically-sized bone defect requires a support scaffold that is well-suited for bone 
regeneration. Ideal bone tissue engineering scaffolds have mechanical properties that 
match those of the host tissue, allow new tissue ingrowth and removal of waste products 
through an interconnected pore volume, exhibit biocompatibility in the implant site, and 
support cell adhesion, proliferation and differentiation (Hutmacher et al. 2001).  The 
most commonly used synthetic polymers for bone tissue engineering are poly(lactic acid) 
(PLA), poly(glycolic acid) (PGA), and their copolymers of poly(lactic-co-glycolic acid) 
(PLGA) (Liu and Ma 2004; Rezwan et al. 2006).  PLGA foams support osteoblastic 
differentiation and bone formation both in vitro (Ishaug et al. 1997) and in vivo (Fialkov 
et al. 2003; Karp et al. 2003).  Poly(ε-caprolactone) (PCL) is another synthetic polymer 
suitable for bone tissue engineering applications, that can be formed into scaffolds by 
fused deposition modeling to create unique architectures and variable pore sizes (Zein et 
al. 2002).  PCL promotes cell-based mineralization both in vitro (Cao et al. 2003; 
Schantz et al. 2003; Byers et al. 2004; Phillips et al. 2006; Zhou et al. 2007) and in vivo 
(Rohner et al. 2003; Schantz et al. 2003; Byers et al. 2006; Rai et al. 2007) and is well 
tolerated in vivo.    Poly(L-lactide-co-D,L-lactide) (PLDL) is a synthetic polymer with 
degradation and mechanical properties appropriate for bone tissue (Cartmell et al. 2004).  
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PLDL promotes cellular mineralization in vitro (Cartmell et al. 2004) and in vivo (Oest et 
al. 2007), and it can be fabricated with longitudinally oriented pores as well as randomly 
dispersed, interconnected pores within the same scaffold  (Lin et al. 2003). 
While synthetic polymeric scaffolds support bone ingrowth and mineralization, 
composite structures and surface modifications improve the osteogenic response.  For 
example, various PCL/ceramic composites, such as PCL/tricalcium phosphate (TCP) and 
PCL/hydroxyapatite increase cell proliferation and matrix deposition rate (Zhou et al. 
2007), alkaline phosphatase activity (Venugopal et al. 2007) and mineralization (Causa et 
al. 2006; Wutticharoenmongkol et al. 2007) compared to PCL scaffolds alone.  
Furthermore, chemical surface modification, such as ion irradiation, enhances cell 
adhesion and osteoblastic differentiation (Amato et al. 2007; Marletta et al. 2007).   
To more specifically modulate the osteoblastic response to synthetic materials, 
surface biofunctionalization strategies which mimic the extracellular matrix allow precise 
control over cell signaling and differentiation (García and Reyes 2005). These strategies 
attempt to recapitulate the signaling environment of the bone ECM and have been used to 
promote osseointegration and bone formation in vivo (Hubbell 2003).  For example, short 
immobilized peptide sequences derived from ECM proteins, such as the RGD sequence 
from fibronectin, have been used to promote cell attachment to titanium implants as an 
improved method of implant fixation and osseointegration (Ferris et al. 1999; Bernhardt 
et al. 2005; Elmengaard et al. 2005).  These strategies take advantage of the specific 
interactions between ECM protein ligands and integrin cell surface receptors. 
 The integrin receptors play a crucial role in cell attachment and ECM-mediated 
cell signaling.  Integrin dimers, consisting of one α and one β subunit, bind specifically 
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to active sites contained within ECM proteins, thereby promoting cell attachment, 
migration, mechanotransduction, and numerous other cell functions (Clark and Brugge 
1995; Hynes 2002).  In particular, the specific interactions of fibronectin with the α5β1 
integrin and of type I collagen with the α2β1 integrin have been shown to mediate 
osteoblast differentiation and subsequent mineralization of osteoblastic and pre-
osteoblastic cells (Moursi et al. 1997; Takeuchi et al. 1997; Xiao et al. 1998; Jikko et al. 
1999; Mizuno et al. 2000).  The α2β1 receptor is highly expressed on the surface of 
osteoblastic cells (Gronthos et al. 1997), and α2β1 activation is presently known to occur 
via binding of distinct adhesive sites contained within collagen I, namely DGEA and 
GFOGER (Xiao et al. 1998; Knight et al. 2000).   Isolation of the active binding 
sequence, GFOGER, via synthetic fabrication of a triple helical GFOGER peptide, allows 
engineered control over osteoblastic differentiation of cells on GFOGER coated 2D 
surfaces (Reyes and García 2003; Reyes and García 2004).  Interestingly, the use of 
GFOGER as an implant coating for titanium tibial plugs in rats enhances osseointegration 
in vivo to levels greater than that of uncoated implants or implants coated with full length 
collagen I (Reyes et al. 2007).  This collagen mimetic strategy for osseointegration 
specifically targets osteoblastic cells through α2β1-mediated signaling by eliminating 
extraneous binding sites contained in the full length protein.  Furthermore, the 
synthetically derived peptide is cheap and easy to fabricate and poses no risk of disease 
transmission.  
 Another collagen mimetic peptide, termed P-15, exhibits collagen-mimetic cell 
signaling when used as a surface coating and promotes osteoblastic differentiation and 
mineralization on anorganic bone matrices in vitro (Qian and Bhatnagar 1996; Bhatnagar 
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et al. 1999; Yang et al. 2004).  Preclinical studies using P-15/ABM implants in 
orthotopic defects have demonstrated successful defect healing, and numerous case 
reports have demonstrated successful healing in humans due to P-15/ABM implants 
(Scarano et al. 2003; Cakmak et al. 2006; Gomar et al. 2007; Trombelli and Farina 
2008).   
Animal models 
Presently, no standard procedure for evaluating bone tissue engineering strategies 
in large and small animal models exists (Reichert et al. 2009).  Researchers often test 
subcutaneous implantations as a first level evaluation of the tissue engineered construct.  
If substantial mineralization is formed subcutaneously, intramuscular implantation may 
be studied at an alternative ectopic site.  However, while these strategies provide initial 
insight into implant-host interaction and can verify survival and function of implanted 
cells, no information regarding successful healing of a large bone defect can be obtained.  
For functional assessment of the implant, an orthotopic model must be used. 
To test the advantage of an implantation strategy in bone, a critically-sized defect 
must be established for each animal model and each anatomic location.  A critically-sized 
defect is defined by the inability of the defect to heal without surgical intervention and is 
the appropriate test bed for bone tissue engineering strategies.  For many models, the 
critical size of the defect is approximately a length 2 to 2.5 times the diameter of the bone 
(Reichert et al. 2009).  For example, a rat femur is approximately 4 mm in diameter, and 
a defect of 8 mm has shown consistent non-union (Oest et al. 2007; Rai et al. 2007).  On 
the other hand, 3-5 mm defects have been tested in rat femurs with varying results. 
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In addition to size of the defect, many other factors must be considered when 
developing an animal model for bone tissue engineering strategies.  Most importantly, the 
model should mimic the human setting for which the strategy is being developed as 
closely as possible.  For example, the cranial defect model provides relevant information 
regarding the healing of craniofacial defects.  However, conflicting evidence regarding 
the role of periosteum, dura mater, and surrounding healthy bone tissue in cranial defect 
healing makes separation of host response from treatment effect difficult in this model 
(Aalami et al. 2003).  In particular, dura mater has been shown to have a significant 
effect on cranial defect healing (Ozerdem et al. 2003).  Therefore, a cranial model may 
not be an appropriate test bed for strategies aimed at healing defects in long bones, where 
contributions from the dura mater are not present. 
 Another aspect for consideration in animal models for bone tissue engineering is 
the methods used to evaluate healing. Many studies that report successful healing of bone 
defects rely solely on a combination of X-ray analysis and histological evaluation as a 
measure of defect healing.  However, these methods do not provide functional 
information, which is necessary to fully evaluate the success of a given treatment strategy 
for bone healing (Liebschner 2004).  Bone quality is a description of all skeletal aspects 
of bone, except bone mass, that affect bone strength, such as shape, size, and trabecular 
connectivity.  (Hernandez and Keaveny 2006). Recent evidence suggests that patients 
with a high level of bone turnover may be at higher risk for bone fracture regardless of 
their bone mineral density (Hernandez 2008).  Therefore, models which only evaluate 
bone volume or percent area of the defect healed via radiographic and histological 
methods are not enough to fully characterize the extent of bone defect healing.  
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Functional mechanical evaluation of bone defects should be used in conjunction with 
other methods for complete analysis of both bone mass and bone quality.   
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EFFECTS OF RAT STRAIN AND CULTURE METHODS ON 
RUNX2-ENHANCED OSTEOBLASTIC DIFFERENTIATION AND 
MINERALIZATION IN BONE MARROW STROMAL CELLS* 
 
Introduction 
Bone marrow stromal cells (BMSCs) are a heterogeneous population of 
progenitor cells, easily obtained from the bone marrow, that have the potential to 
differentiate along several tissue lineages, including adipogenic, chondrogenic, and 
osteogenic (Pittenger et al. 1999).  Because of their stem cell-like nature, BMSCs have 
been explored as a possible cell source for many tissue engineering applications, 
including bone tissue engineering (Haynesworth et al. 1992; Bruder et al. 1994; Quarto et 
al. 2001; Derubeis and Cancedda 2004).  However, in vitro expansion of BMSCs, a 
necessary step in obtaining sufficient cell numbers for therapeutic applications, results in 
a significant decrease in BMSC proliferation rate and osteoblastic differentiation and 
mineralization (Banfi et al. 2000; Lim et al. 2006).  To overcome these limitations, 
Runx2 genetic modification has been employed as a method of maintaining the 
osteogenic potential of these cells even after multiple passages in vitro (Byers and García 
2004; Byers et al. 2006). 
Runx2/Cbfa1 is an osteoblast-specific transcription factor that upregulates the 
expression of many osteoblast-specific genes, such as osteopontin, osteocalcin, bone 
sialoprotein and collagen I (Ducy et al. 1997).  The role of Runx2 in osteoblastic 




differentiation has been demonstrated both in vitro and in vivo, and in both human (Shui 
et al. 2003) and rodent systems (Otto et al. 1997).  Furthermore, skeletal abnormalities 
have been observed in the absence of Runx2 function.  For example, transgenic mice 
expressing a dominant negative form of Runx2 develop abnormally even after normal 
embryonic development (Ducy et al. 1999).  Homozygous deletion of Runx2 in mice 
results in embryonic lethality and a complete lack of bone formation (Komori et al. 1997; 
Otto et al. 1997), while heterozygous Runx2 mutant mice show impaired mineralization 
and bone formation compared to wild-types (Otto et al. 1997).  Finally, the human 
disease, cleidocranial dysplasia, occurs as a result of genetic mutations in Runx2 (Lee et 
al. 1997; Mundlos et al. 1997; Zhang et al. 2000).  Forced overexpression of Runx2, 
therefore, has been used to promote osteogenesis in vitro and in vivo in bone marrow 
stromal cells (Byers and García 2004; Zheng et al. 2004; Zhao et al. 2005; Byers et al. 
2006).  Interestingly, this phenomenon has also been demonstrated in non-osteoblastic 
cell lineages, such as myoblasts and dermal fibroblasts (Gersbach et al. 2004; Gersbach 
et al. 2004; Phillips et al. 2007), demonstrating the role of Runx2 as a molecular switch 
in osteoblast biology (Ducy 2000). 
Although Runx2 genetic engineering provides a way to overcome the reduced 
osteogenic potential of in vitro expanded-BMSCs, it should be noted that in vitro 
expansion is not the only variable that affects BMSC function.  Isolation and culture 
procedures strongly influence BMSC growth rate and osteogenic differentiation potential 
(Phinney et al. 1999) as well as alkaline phosphatase-positive colony forming units 
(CFUs) (Muschler et al. 1997).  Culture conditions, such as serum source, media 
composition and even media volume, modulate osteogenic differentiation (Jaiswal et al. 
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1997; Anselme et al. 2002; Mendes et al. 2002; Abdallah et al. 2006).  Finally, donor age 
has been shown to affect the growth rate of human BMSCs older than 40 years of age 
(Mendes et al. 2002), but not that of BMSCs when donors were younger than 40 years of 
age (Phinney et al. 1999).  Taken together, these studies illustrate that cell source (i.e. 
donor) and culture conditions affect the function of BMSC populations. 
In the present work, we examined the osteogenic differentiation and 
mineralization capacity of unmodified and Runx2-modified BMSC populations isolated 
from commonly used strains of rats.  We compared cells isolated from Lewis rats, an 
inbred strain, to those isolated from Wistar rats, an outbred strain.  We demonstrate that 
the BMSC population derived from Wistar rats has a greater propensity for retroviral 
Runx2 transduction than the population derived from Lewis rats, but that Lewis BMSC 
populations have a greater capacity for subsequent osteoblastic differentiation than 
Wistar BMSC populations. 
Materials and Methods 
Cell harvest and isolation 
Rat BMSCs were isolated from the hind legs of young Lewis or Wistar rats 
(Charles River Labs) by commonly used methods (Javazon et al. 2001; Byers and García 
2004).  Briefly, the rats were euthanized by CO2 asphyxiation (protocol approved by the 
Institutional Animal Care and Use Committee at the Georgia Institute of Technology), 
and the hind-limbs removed, taking care to minimize bleeding and subsequent clotting.  
Surrounding soft tissue was removed from each bone, and the separated femurs and tibias 
were soaked in cell culture media consisting of αMEM (Invitrogen) + 1% penicillin-
streptomycin (Invitrogen) + 10 or 20% fetal bovine serum (FBS – HyClone).  The 
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epiphyses of each bone were removed and the marrow was flushed from the diaphysis of 
the bone into a sterile tube.  The marrow pellet was centrifuged, resuspended, and then 
transferred to tissue culture-grade polystyrene (Corning). 
Two different methods of stromal cell isolation were tested.  Both methods begin 
as described above but differ after plating.  Method 1 involves a 30 minute incubation 
step, whereby plated cells are maintained at 37oC for 30 minutes, after which time, non-
adherent cells are removed and replated, while those that have adhered are discarded.  
This procedure is designed to remove monocytes/macrophages from the heterogeneous 
BMSC population.  Method 2 does not include this adhesion-selection step, and cells are 
plated onto tissue culture-grade polystyrene immediately following centrifugation. 
The following three strain/culture condition groups were examined: 
1. Lewis BMSC harvested without the 30-min adhesion-selection step, isolated in 
20% FBS, then switched to 10% FBS after one week.  This group is referred to as 
Lewis (serum). 
2. Lewis BMSC harvested without the 30-min adhesion-selection step, isolated and 
cultured in 10% FBS throughout culture.  This group is referred to as Lewis. 
3. Wistar BMSC harvested with the 30-min adhesion-selection step, isolated and 
cultured in 10% FBS throughout culture.  This group is referred to as Wistar. 
Runx2 retroviral transduction 
Following isolation, cells were expanded to passage 3 or passage 5 in αMEM + 
1% penicillin-streptomycin + 10% FBS (Invitrogen), and then plated at 5 000 cells/cm2 in 
6 well plates (Corning) coated with type I collagen (MP Biomedicals).  For each 
strain/culture condition, four treatment groups were examined: (i) Runx2-engineered 
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cells, (ii) Runx2-engineered cells + dexamethasone (dex, 10 nM), (iii) unmodified cells, 
and (iv) unmodified cells + dex.  Dex is a synthetic glucocorticoid that induces 
osteoblastic differentiation of BMSCs in vitro (Maniatopoulos et al. 1988; Cheng et al. 
1994).  Genetically engineered cells were transduced with Runx2 retrovirus as previously 
described (Byers et al. 2002).  Two days after transduction, culture media was 
supplemented with 50 µg/mL ascorbic acid and 3 mM Na β-glycerophosphate.  All 
media supplements were purchased from Sigma.  Media was changed every 2-4 days. 
Flow cytometry for transduction efficiency 
Our Runx2 retrovirus has an internal ribosomal entry site that encodes for 
enhanced green fluorescent protein (eGFP) as a marker of Runx2 transduction (Byers et 
al. 2002).  To measure Runx2 transduction efficiency, eGFP expression was measured by 
flow cytometry.  Three days after Runx2 transduction, cells were trypsinized (0.05% 
trypsin/EDTA – Invitrogen) and resuspended in phosphate buffered saline (PBS – 
Invitrogen) with 10% FBS.  Cell suspensions were then centrifuged for 5 minutes at 200-
300g, resuspended in PBS and then passed through a 40 µm filter (BD Falcon).  eGFP 
fluorescence was measured on a flow cytometer (Becton Dickinson, BD LSR II), and 10 
000 events were measured for each sample.  Data analysis was performed using WinMDI 
v.2.8, and graphs were made in FlowJo v.7.2.1.  
Alkaline phosphatase activity 
Alkaline phosphatase (ALP) activity was evaluated as an early marker of 
osteoblastic differentiation at 7 days after Runx2 transduction (Byers et al. 2002).  
Cultures were rinsed with PBS, then lysed with 50 mM ice cold Tris-HCl.  Lysates were 
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sonicated 2 times each for 10 seconds at 5 Watts and then centrifuged at 10 000g for 5 
minutes.  The supernatant, containing the soluble protein component, was then frozen at -
20oC. 
For each sample, total protein concentration was determined by averaging the 
results of a bicinchoninic acid (BCA) reaction (Pierce Biotechnology, Micro BCA 
Protein Assay kit #23235) with those obtained from a Nanodrop (ND-1000 
Spectrophotometer).  To measure ALP activity, 2.5 µg of total protein was added to 60 
µg/mL 4-methyl-umbelliferyl-phosphate, a fluorescent substrate for the ALP reaction, in 
diethanolamine buffer (10 mM diethanolamine, 0.5 mM MgCl2, 0.2 M NaHCO3, 
pH=9.5).  Samples were incubated at 37oC for 40 minutes in the dark to allow the 
reaction to occur.  Activity was measured as relative fluorescence units on a Bio Assay 
Reader (Perkin Elmer, HTS 7000 Plus) and standardized using purified calf intestinal 
ALP (Sigma). 
von Kossa staining for mineralization 
Twenty one days after Runx2 transduction, cultures were stained for phosphate 
deposits, indicative of mineral formation, by von Kossa staining (Byers et al. 2002).  
Briefly, plates were rinsed with PBS and then fixed in 70% ethanol at 4oC overnight.  
After fixation, plates were rinsed with ddH2O, stained with 5% AgNO3 for 30 minutes on 
a light table, rinsed again with ddH2O, fixed with 5% NaS2O3 for 2 minutes, and rinsed 
again with ddH2O.  Plates were stored in the dark until completely dry.  Images were 
captured with a digital camera (Kodak Digital Science DC120 Zoom Digital Camera).  
Mineral area was quantified using an inverted microscope (Nikon Eclipse TE300) with 




All statistics were performed using Systat v.11.00.01.  For flow cytometry data, 
ANOVA analysis was performed using the post-hoc Tukey method to determine 
differences between groups.  A p-value < 0.05 was considered significant.  For ALP 
activity and mineralization, data was divided into three groups: treatment (4 levels: 
Control, Control+dex, Runx2, Runx2+dex), strain/harvest (3 levels: Lewis (serum), 
Lewis, Wistar), and passage (2 levels: passage 3 and passage 5).  These three groups were 
analyzed by a general linear model ANOVA to determine overall differences between the 
levels in each group. 
Results 
Runx2 transduction efficiency 
To quantify the transduction efficiency of the Runx2 retrovirus, flow cytometry 
analysis was used to determine the percentage of cells expressing eGFP after 
transduction.  Unmodified BMSCs (no Runx2 transduction) were used as a negative 
control, and the top 2% of cells in each control population were used to set the lower 
limits for transduction.  Figure  3.1 shows flow cytometry histograms of both control and 
Runx2 transduced cells for all strain/harvest groups. 
For all groups, passage 3 cells demonstrated significantly different transduction 
efficiencies when compared to passage 5 cells within the same strain/harvest group.  
Interestingly, Wistar cultures at passage 5 showed greater transduction efficiency 
compared to Lewis and Lewis (serum) cultures at the same passage.  This result could be 
due to differences in proliferation rate, which affects retroviral transduction, or 
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differences in donor strain or culture/isolation procedures.  Finally, passage 3 Lewis 
(serum) cultures showed significantly less transduction efficiency than the other two  
 
Figure  3.1.  Runx2 retroviral transduction efficiency is differentially modulated by cell passage and 
strain/harvest procedures.  § Different from other harvest groups within the same passage.  Furthermore, 
transduction efficiency is significantly different at P3 than at P5 for all groups. * Different from P3 within 
the same harvest group. p<0.05, n=3.  Error bars represent standard deviation. 
 
groups at the same passage.  These results indicate that a change in media components 
(i.e. 20% serum switched to 10%) significantly impacts transduction efficiency. 
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Alkaline phosphatase activity 
Alkaline phosphatase (ALP) activity was examined at 7 days after Runx2 
transduction as a marker of early osteoblastic differentiation.  Runx2 treatment 
significantly increased ALP activity both with and without dexamethasone (Figure  3.2).  
Further analysis by general linear model ANOVA showed that ALP activity was also 
significantly modulated by strain/harvest group as shown in the inset in Figure  3.2A.  
This statistical analysis allowed the simultaneous comparison of several experimental 
groups containing multiple levels, and the variance of each group was taken into account 
when calculating the significance.    Finally, passage did not have a significant effect on 
ALP activity under these conditions. 
 
Figure  3.2.  Treatment with Runx2 significantly increases alkaline phosphatase (ALP) activity after 7 days 
for (A) passage 3 cultures and (B) passage 5 cultures.  Furthermore, as shown in the inset, strain/harvest 
group has an overall significant effect on ALP activity.  p<0.05, n=3.  Error bars represent standard 
deviation. 
von Kossa staining for mineralization 
Cultures were maintained for 3 weeks under osteogenic conditions to examine 
mineral deposition, which was assessed by von Kossa staining and image analysis.  von 
Kossa analysis revealed differences in mineralization among experimental groups (Figure 
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 3.3A).  The percentage of mineralized area on each plate was quantified for passage 3 
(Figure  3.3B) and passage 5 (Figure  3.3C) cultures.  Runx2 treatment, strain/harvest 
conditions, and passage all had a significant effect on mineralization.  Overall differences 
for strain/harvest group are illustrated in the inset in Figure  3.3B. 
 
Figure  3.3.  Unmodified Lewis cultures (control and control+dex) display the greatest amount of 
mineralization compared to unmodified Lewis (serum) and Wistar cultures.  Treatment with Runx2 + dex 
increases mineralization for all groups.  von Kossa staining is shown in (A).  Mineralization was quantified 
by image analysis and results are shown for (B) P3 cells and (C) P5 cells.  Using a general linear model for 
ANOVA analysis, strain, passage and treatment all showed overall significant differences.  Overall strain 




The trends observed for mineralization match those for ALP activity, namely that 
Runx2 treatment with and without dexamethasone significantly increased both ALP 
activity and mineralization.  Furthermore, Lewis cultures displayed significantly greater 
ALP activity and mineralization compared to Lewis (serum) and Wistar cultures.  These 
results demonstrate that both early (ALP) and late (mineral) markers of osteogenic 
differentiation are affected in the same manner by Runx2 treatment and strain/harvest 
procedures in this study.  Finally, Lewis BMSCs in combination with Runx2 genetic 
engineering produced the most mineral. 
Discussion 
In this study we demonstrate differences in the osteogenic differentiation ability 
of bone marrow stromal cells harvested from different strains of rat using different 
methods of isolation.  Although it has already been established that cell source has a 
significant effect on the function of a BMSC population (Phinney et al. 1999; Anselme et 
al. 2002), cell populations derived from different animal strains have not yet been 
compared.  Our work suggests that donor strain differences may have a significant effect 
on the function of BMSC populations. 
The current work shows that overall mineralization of Lewis BMSC cultures is 
significantly greater than that of Wistar BMSCs, suggesting a difference between BMSC 
populations harvested from these two strains of rats.  These differences are most 
noticeable for unmodified passage 5 cells (control and control + dex conditions), whereas 
Runx2 treatment with and without dex essentially eliminated the differences between the 
two strains.  The mechanistic reasons for these apparent strain differences in unmodified 
rat BMSCs are not yet clear; however, strain differences in rats cause a number of 
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physiological differences, including behavioral differences (Brimberg et al. 2007; Kosten 
et al. 2007), differences in platelet aggregration and thrombus formation (Sudo et al. 
2007), skeletal development (DeMoss and Wright 1998), and ectopic bone formation in 
response to BMP9 (Li et al. 2003), among others. These results taken together with this 
study suggest that strain differences play an important role in many biological systems of 
the rat.  Therefore, regarding human tissue engineering therapies, results validated in pre-
clinical studies may be largely dependent on the strain of the animal used. 
It is well-established that serum concentration and differences in serum source, 
such as the specific lot of serum, influence mammalian cell culture.  Here we report that 
changing the serum concentration from 20% to 10% after one week had a significant 
effect on BMSC retroviral transduction, alkaline phosphatase activity and matrix 
mineralization.  The switch in serum concentration from 20% to 10% had a negative 
effect when compared to sustained culture in 10% serum.  Although these two cultures 
were initially expanded for one week in different serum concentrations, they were both 
cultured in 10% serum after one week.  This indicates that a change in serum 
concentration may have a greater effect on cell function than the concentration alone. 
Although there may be differences in the osteogenic capacity of BMSCs derived 
from Lewis versus Wistar rats, a limitation of this study is that our isolation methods 
differed slightly between Lewis and Wistar cells.  Our harvest from Wistar rats included 
a 30 minute adhesion selection step whereby cells that were readily adherent to the plates 
were discarded.  In contrast, our harvest of Lewis cells did not include this step.  The 
inclusion of this adhesion selection step is meant to remove monocytes/macrophages 
from the heterogeneous BMSC population; however, it is possible that in discarding these 
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readily adherent cells, many of the desired osteogenic cells of the population may have 
been discarded as well.  Therefore, the differences observed in this study could have been 
due to either strain or isolation methods or a combination of both.  Further investigation 
is required to fully elucidate the cause of the observed differences. 
In conclusion, we have demonstrated significant differences in osteoblastic 
differentiation and mineralization of BMSC populations due to differences in donor rat 
strain and culture conditions. Although BMSCs are a robust potential cell source for 
orthopaedic tissue engineering applications due to their ability to differentiate into 
functional osteoblastic cells, differences between donors and differences in culture and 
isolation procedures have a significant impact on cellular differentiation and 
mineralization.  Therefore, donor strain and isolation procedures should be carefully 
considered when choosing a cell source for pre-clinical tissue engineering research.  The 
ultimate goal in tissue engineering is the development of therapies for human disease 
states; therefore, the significance of the current work emphasizes the importance of 
choosing an appropriate animal model for a particular human application.  With regard to 
bone tissue engineering, certain rat strains may be more conducive to in vitro BMSC 
mineralization than others.  The current study demonstrates that cell type (i.e. BMSC) is 
not the only criterion necessary for defining a cell source for orthopaedic tissue 
engineering applications and that donor strain and isolation procedures also have a 
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RUNX2 OVEREXPRESSION IN BONE MARROW STROMAL 
CELLS ACCELERATES BONE FORMATION IN CRITICALLY-
SIZED RODENT FEMORAL DEFECTS 
 
Introduction 
 The repair of large bone defects in humans remains a significant clinical problem 
despite successful healing of defects treated with auto- and allografts.  Although 
autografts contain the appropriate cues for osteogenesis and elicit no immunogenicity, 
donor site morbidity and pain affect as many as 30% of patients who have undergone a 
bone harvest from the iliac crest (Gottfried and Dailey 2008; Rawashdeh and Telfah 
2008).  Allografts address these sourcing issues but are further complicated by poor 
mechanical properties, increased rates of resorption, and increased risk of infection 
(Sorger et al. 2001; Mankin et al. 2005).  As an alternative approach for bone repair, 
tissue engineering and regenerative medicine strategies are being developed to address 
the problems associated with current bone grafting procedures (Hutmacher and García 
2005; Awad et al. 2007; Cancedda et al. 2007; Kimelman et al. 2007). 
 For successful repair and remodeling of large bone defects, a cell population 
capable of producing and remodeling bone must be present in the defect site.  These cells 
can either be recruited from host tissues or implanted via surgical intervention.  Bone 
marrow stromal cells (BMSCs) offer an attractive solution to cell sourcing for bone tissue 
engineering because they are part of a multipotential cell population that contributes to 
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the early stages of fracture healing in bone (Einhorn 1998), and human BMSCs can be 
isolated from bone marrow and delivered directly to a defect site to induce healing 
(Muschler et al. 1997; Smiler and Soltan 2006).  BMSCs have the capability of 
differentiating into osteoblasts, among other cell types of the mesodermal lineage, and 
they mineralize constructs both in vitro and in vivo (Goshima et al. 1991; Ishaug et al. 
1997; Krebsbach et al. 1997; Pittenger et al. 1999; Cartmell et al. 2004).  BMSCs also 
enhance bone healing in critically-sized orthotopic defects in rodents and large animals 
compared to treatment with a scaffold alone (Werntz et al. 1996; Bruder et al. 1998; Kon 
et al. 2000; Petite et al. 2000).  Recently, Marcacci et al. have reported successful healing 
of large bone defects in humans treated with autologous BMSCs seeded on bioceramic 
scaffolds.  These implantations were initially reported in 2001, and a 6-7 year follow-up 
of each patient demonstrated that complete bone implant integration was achieved in all 
patients as determined by radiography and CT analysis (Quarto et al. 2001; Marcacci et 
al. 2007). 
 The success of these implants makes a strong case for the use of autologous 
BMSCs in treating large bone defects in humans.  However, multiple factors affect the 
inherent ability of BMSCs to differentiate into osteoblasts.  For example, in vitro 
expansion of BMSCs, a necessary step to obtain sufficient numbers for implantation, 
causes dedifferentiation and subsequent loss of mineralization capacity (Banfi et al. 2000; 
Derubeis and Cancedda 2004; Yeon Lim et al. 2006).   Furthermore, the mineralization 
potential and proliferation rate of BMSCs varies widely with individual donors and is 
significantly affected by donor age (Phinney et al. 1999; Mendes et al. 2002; Kretlow et 
al. 2008).  These variations in BMSC function imply that the treatment of large bone 
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defects with autologous BMSCs may not produce effective results for all patients.   A 
method which overcomes these difficulties with BMSCs would provide great benefit to 
clinical bone healing. 
 To address these limitations with BMSCs, extensive work has focused on BMP 
delivery to BMSCs for upregulation of osteoblastic differentiation (Hanada et al. 1997; 
Gazit et al. 1999; Huang et al. 2005; Edgar et al. 2007; Hsu et al. 2007).  However, the 
diffusion of these soluble factors away from a defect site makes the effective dosage for 
human BMP treatment very high, which in turn makes treatment with BMPs an 
expensive therapy (Bishop and Einhorn 2007). Furthermore, as a soluble factor, diffusion 
of BMP away from the delivery site decreases the amount of bone formed in an implant 
and may lead to unregulated signaling in remote sites (Uludag et al. 2000).   
Alternatively, the type 2 runt-related Cbfa1 gene, Runx2, encodes an osteoblast-specific 
transcription factor, which works intracellularly to upregulate a host of bone specific 
genes, including osteocalcin and collagen I (Ducy et al. 1999).  Runx2 plays an important 
role in both bone development and bone remodeling/repair (Ducy 2000).  For example, 
homozygous deletion of Runx2 in mice causes the formation of a completely non-
mineralized, cartilaginous skeleton and results in immediate postpartum death (Komori et 
al. 1997; Otto et al. 1997).  Meanwhile, mice heterozygous for Runx2 display a 
pathology similar to that observed in the sketetal disease cleidocranial displasia (Mundlos 
et al. 1997; Otto et al. 1997).  In fact, the human disease, cleidocranial dysplasia, occurs 
as a result of genetic mutations in Runx2 (Lee et al. 1997; Mundlos et al. 1997; Zhang et 
al. 2000).  The role of Runx2 as an osteoblastic transcription factor in human BMSCs has 
been demonstrated in vitro via DNA binding assays (Shui et al. 2003).  Furthermore, 
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dominant negative expression of Runx2 after osteoblast differentiation causes skeletal 
abnormalities (Ducy et al. 1999), while ex vivo overexpression of Runx2 in both 
osteoblastic and non-osteoblastic cells promotes upregulation of bone-specific genes and 
subsequent mineralization (Xiao et al. 1999; Byers et al. 2002; Gersbach et al. 2004; 
Phillips et al. 2007).  Finally, overexpression of Runx2 in BMSCs accelerates 
osteoblastic differentiation and subsequent mineralization both in vitro and in vivo when 
compared to unmodified BMSCs (Byers et al. 2004; Zhao et al. 2005), making Runx2 
overexpression an attractive option for regulating BMSC function. 
 Recently, our group and others have reported significant healing of critically-
sized defects in a calvarial defect model treated with BMSCs engineered to overexpress 
Runx2 (Zheng et al. 2004; Byers et al. 2006; Zhao et al. 2007).  However, results 
obtained from calvarial defect studies do not necessarily translate to healing in long 
bones due to the involvement of the dura mater in healing cranial defects (Aalami et al. 
2003).  In this study, we examine the effect of constitutive overexpression of Runx2 in 
BMSCs implanted in critically-sized segmental defects in rat femurs.  This model 
provides a more rigorous test bed than cranial defects by eliminating contributions to 
healing from the dura mater.  This segmental defect study of Runx2-modified BMCSs for 
the treatment of large bone defects provides better insight into this alternative cell-based 
gene therapy method for clinical bone defect healing. 
Materials and Methods 
Cell harvest and isolation 
Rat BMSCs were isolated from the hind legs of young Lewis rats (Charles River 
Labs) by commonly used methods (Javazon et al. 2001; Byers and García 2004).  Briefly, 
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the rats were euthanized by CO2 inhalation (Georgia Tech IACUC-approved protocol), 
and the hind limbs removed, taking care to minimize bleeding and subsequent clotting.  
Surrounding soft tissue was removed from each bone, and the separated femurs and tibias 
were soaked in cell culture media consisting of αMEM (Invitrogen) + 10% fetal bovine 
serum (FBS – HyClone) + 1% penicillin-streptomycin (Invitrogen) + 0.3 µg/mL 
fungizone.  The distal end of each bone was removed and the marrow was flushed from 
the diaphysis via centrifugation into a sterile tube.  The marrow pellet was then 
resuspended, and transferred to tissue culture-grade polystyrene (Corning).  Three days 
after harvest, plates were rinsed twice in PBS to remove non-adherent hematopoietic 
cells, and fresh media was added.  Media was changed every 3 days.  When plates were 
80-90% confluent, passage 0 cells were cryopreserved in 10% DMSO in FBS at -80oC 
overnight, then transferred to liquid nitrogen for long term storage. 
Scaffold fabrication 
 Polycaprolactone (PCL) scaffolds were produced in 9 mm thick sheets by fused 
deposition modeling as described previously (Zein et al. 2002).  Sheets were cut into 
scaffolds using a 4 mm diameter dermal biopsy punch (Miltex).  MicroCT analysis was 
used to characterize the structural parameters of the scaffolds (Figure  4.2C).  For in vivo 
studies, scaffolds were 81-85% porous, average pore size was 890 µm and average rod 
thickness was 310 µm. 
 For all studies, scaffolds were cleaned in 70% ethanol for 30 minutes, rinsed 3 
times in sterile water to remove ethanol, then soaked in PBS for 10-30 minutes prior to 
cell seeding.  For in vivo studies, an additional step was added prior to scaffold 
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sterilization for endotoxin removal.  For this step, scaffolds were rinsed in 70% ethanol 
for 4 days on a shaker plate, and ethanol was replaced every day. 
To produce collagen meshes within each PCL scaffold, a collagen solution was 
polymerized inside the scaffolds, then lyophilized as previously described (Porter et al. 
2007).  Briefly, a sterile solution of 1.5 mg/mL type I collagen (MP Biomedicals) was 
polymerized inside sterile PCL scaffolds at 37oC for 30 minutes.  Constructs were then 
frozen for 1 hour at -80oC and lyophilized overnight to produce a mesh of collagen within 
the scaffolds. 
Retroviral transduction 
 The Runx2 type II MASNSLF isoform was expressed via the pTJ66 vector as a 
single bicistronic mRNA sequence encoded by murine cDNA (Figure  4.2A).  An internal 
ribosomal entry site, located downstream from and adjacent to the Runx2 insert, allowed 
co-expression of a fusion protein of zeocin resistance and enhanced green fluorescent 
protein (eGFP).  eGFP expression was quantified via flow cytometry and used as a 
measure of Runx2 transduction efficiency (Byers et al. 2002; Gersbach et al. 2004).  
Empty pTJ66 vector, which was missing the Runx2 insert but still encoded the fusion 
protein, was used as an empty vector control (Phillips et al. 2007). 
 To package Runx2 retrovirus, ΦNX helper cells, stably transfected with the 
Runx2 plasmid, were grown to sub-confluency in DMEM + 10% FBS + 1% P/S.  Twenty 
four hours before the first viral harvest, media was changed and cells were transferred to 
a 32oC incubator to minimize heat-induced viral degradation.  To harvest virus, media 




 To transduce primary BMSCs with Runx2 or empty-vector virus, bone marrow 
stromal cells were expanded to passage 3, then trypsinized and seeded into T-75 flasks at 
a density of 5,000 cells/cm2.   One day after seeding into flasks, media was replaced with 
retrovirus supplemented with 0.4 µg/mL polybrene, as previously described (Byers et al. 
2002).  Briefly, flasks were incubated with viral media at 32oC for 15 minutes, then 
centrifuged at 2500 RPM for 30 minutes.  Viral media was then replaced with fresh 
αMEM + 10% FBS + 1% P/S + 0.3 µg/mL fungizone/amphotericin B, and cells were 
incubated at 37oC.  After 12 hours, a second transduction was performed.  Two days after 
transduction, cells were trypsinized from flasks and seeded onto scaffolds or analyzed for 
eGFP expression by flow cytometry. 
Cell seeding on scaffolds 
Immediately prior to cell seeding, PCL-collagen scaffolds were pre-wet in PBS, 
then wicked on Kimwipes to remove excess fluid.  Unmodified, Runx2-modified and 
empty-vector-modified cells (passage 4) were trypsinized and seeded at 500,000 cells per 
scaffold in 50 µL of media (25 µL per side).  Scaffolds were placed in scaffold holders 
inside 24 well plates and incubated at 37oC to allow cell attachment to the scaffolds.  
After 30 minutes of incubation, 2 mL of media were added to each well for complete 
submersion of each scaffold.  Media was changed every 3 days. 
To ensure equal cell numbers were seeded onto all scaffolds, unmodified BMSCs 
were seeded onto PCL-collagen scaffolds, as described above, in three separate batches, 
n=4 scaffolds for each batch.  Three days after cell seeding, DNA content on each batch 
of scaffolds was analyzed via Picogreen staining (Quant-iTTM Picogreen® dsDNA Assay 
Kit – Molecular Probes) as previously described (Gersbach et al. 2004; Phillips et al. 
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2006).  Briefly, constructs were rinsed in PBS, then frozen at -80oC.  Thawed samples 
were dried in a Savant DNA120 SpeedVac Concentrator (Thermo Electron Corporation), 
then digested in 700 µg/mL Proteinase K (Promega) for 48 hours in a 45oC water bath.  
Picogreen staining was used to quantify average DNA content/cell numbers on each 
batch of scaffolds.  No differences in cell number were observed among groups (data not 
shown), confirming that cell seeding was reproducible across multiple batches. 
Flow cytometry for transduction efficiency 
Three days after Runx2 or empty-vector transduction, cells were trypsinized 
(0.05% trypsin/EDTA – Invitrogen) and resuspended in PBS with 10% FBS.  Cell 
suspensions were centrifuged for 5 minutes at 200-300g, resuspended in PBS and then 
passed through a 40 µm filter (BD Falcon).  eGFP fluorescence was measured on a flow 
cytometer (Becton Dickinson, BD LSR II), and 10,000 events were measured for each 
sample.  Data analysis was performed using WinMDI v.2.8.  
Live/Dead staining 
Cell viability on PCL scaffolds was assessed using the Live/Dead kit (Invitrogen).  
Unmodified and Runx2 modified cells were seeded onto PCL scaffolds with and without 
collagen meshes.  Three days after seeding, constructs were rinsed 3 times in PBS, then 
stained with 4 µM calcein and 4 µM ethidium homodimer in PBS for 45 minutes at room 
temperature.  After staining, constructs were rinsed 3 times in PBS, then imaged on a 
confocal microscope (Zeiss LSM 510 NLO).  LSM 5 Image Browser was used to stack 




Segmental Defect surgery 
 Femoral defects were created bilaterally as previously described (Oest et al. 
2007).  Briefly, 13- to 15-week old female Lewis rats were anesthetized using isoflurane, 
and the hind limbs were shaved and swabbed with cycloheximide and alcohol to prepare 
the skin for incision.  An anterior incision was made from the hip to the knee to allow 
blunt separation of the quadriceps muscles, exposing the femur (Figure  4.1A).  Before the 
defect was created, a modular fixation device was attached to the bone for mechanical 
support.  The device consisted of two stainless steel plates affixed directly to the bone via 
screws and one polysulfone plate, which spanned the defect and was attached to the 
stainless steel plates (Figure  4.1B).  Use of this modular system was advantageous for 
postmortem mechanical testing because the polysulfone plate could be removed before 
defect testing without removing the screws or stainless steel plates from the bone, thus 
avoiding any incidental damage to the repair tissue prior to testing.  Furthermore, use of a 
polysulfone plate for support allowed non-invasive in vivo X-ray analysis of defects due 
to the low X-ray attenuation of polysulfone.  After the fixation device was attached, an 
8.0-mm segment of bone was removed via bone saw, and a scaffold was press fit into the 
defect (Figure  4.1A).  Notches in the polysulfone plate, spaced 8.0-mm apart, ensured 
each defect was consistently created the same length (Figure  4.1B).  Muscle was closed 
around the plate and defect using Vicryl sutures, and the skin was closed using sutures 





Figure  4.1.  Surgical procedure for critically-sized segmental defects in rat femurs.  (A) Each defect is 
stabilized by a fixation plate. (i) Blunt dissection of the quadriceps exposes the femur and enables 
placement of the fixation plate.  (ii) An 8.0 mm segment is removed from the femur via bone saw, and (iii) 
scaffolds are press fit into the defect.  (B) An explanted femur shows the modular fixation plate attached to 
the bone via stainless steel screws.  Notches in the polysulfone plate (marked with arrows) are spaced 8.0 
mm apart ensuring each defect is created at the same size. 
 
For in vivo studies, five groups were tested, consisting of 4 PCL-collagen scaffold 
groups each with a different cell condition, and one empty defect control group.  For the 
empty defect group, the surgical procedure remained the same, but no scaffold or cells 
were placed in the defect.  The groups tested were PCL-scaffolds seeded with (i) 
unmodified BMSCs, (ii) Runx2-modified BMSCs, (iii) empty vector-modified BMSCs or 




Table  4.1.  Outline of experimental groups for in vivo segmental defects. 
 
 
 Following surgery, animals were given 3 daily doses of buprenorphine at 0.03 
mg/kg for 2 consecutive days and 3 doses of 0.01 mg/kg on the third day to control pain.  
Animals were monitored daily for signs of pain and distress, progress of wound closure, 
regular eating habits and normal ambulation.  A small percentage (< 8%) of rats 
developed infections in or around the surgery site, or experienced mechanical failure of 
the fixation device.  These animals were removed from the study and euthanatized, and 
any data collected from these animals was excluded.  Two weeks post surgery, when skin 
wounds had completely healed, animals were anesthetized with isoflurane and wound 
clips were removed.  At 4, 8, and 12 weeks post-surgery, animals were anesthetized with 
isoflurane and the hind legs were scanned via radiography and microCT as described 
below.  Twelve weeks post-surgery, animals were euthanized by CO2 inhalation, and the 
femurs, along with surrounding muscle tissue, were harvested for postmortem microCT 
evaluation, histology, FTIR analysis and mechanical testing.  
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Radiography and MicroCT Analysis 
 Every 4 weeks following surgery, 2-dimensional X-ray images of each sample 
were non-invasively obtained using an MX-20 Specimen Radiography System (Faxitron 
X-ray Corporation) to make gross morphological observations of bone formation in each 
defect site.   For X-ray analysis, animals were anesthetized in a gas chamber filled with 
5% isoflurane and maintained under anesthesia using 2% isoflurane flow into a face 
mask.  Each hind leg of anesthetized animals was scanned for 15 s with an X-ray beam 
energy of 23 kV. 
 In addition to radiographic imaging, samples were non-invasively analyzed every 
4 weeks post-surgery by microCT using a vivaCT 40 (Scanco Medical) to quantify bone 
volume in each defect site.  For microCT, animals were anesthetized in the same manner 
as for radiography and placed in a rodent holder with one leg outstretched for scanning.  
The defect area in between the stainless steel plates of the fixation device was imaged 
with an X-ray beam energy of 55 kVp and intensity of 109 µA, and the integration time 
was 200 ms.  Scanning resolution was 38 µm.  After imaging was complete, noise was 
reduced from 3-dimensional reconstructions of each scan by applying a Gaussian filter 
(sigma=1.2, support=2) using the Scanco Medical µCT Evaluation Program.  Images 
were thresholded at 270 mg HA/ccm to isolate mature bone from soft tissue and the 





 Following euthanasia, samples for histological analysis were fixed in 10% neutral 
buffered formalin immediately after harvest.  One day after fixation, soft tissue was 
removed, and specimens were placed in fresh formalin.  Prior to embedding, fixed tissues 
were scanned ex vivo in formalin via microCT as described above to allow matching of 
histological sections with microCT slices.  After scanning, specimens were dehydrated in 
a series of alcohols, cleared in xylene, and embedded in methyl methacrylate (MMA).  
Ground sections, 50-80 µm thick, were prepared by Wasatch Histo Consultants, Inc. 
(Winnemucca, NV) and stained using Sanderson’s Rapid Bone StainTM and a van Gieson 
counterstain (Reyes et al. 2007).  Stained histological sections were then matched to 
thresholded microCT scans to confirm that microCT analysis was representative of 
mature bone. 
FTIR spectroscopy 
 Explanted samples for FTIR analysis were wrapped in PBS-soaked gauze and 
frozen at -20oC until use.  Upon thawing, chips of mineralized tissue were removed from 
the defect area of each sample using a bone cutter.  Care was taken to remove only newly 
formed mineralized tissue in the defect area and no native host bone.  Mineral chips were 
fixed in ethanol, then dried overnight at 50oC, ground with a mortar and pestle, pressed 
into KBr pellets, and read on a Nexus 470 FT-IR (Thermo Nicolet) using 64 scans at 4 
cm-1 resolution.  Native bone from age-matched Lewis rat femurs were used as positive 
controls for FTIR bone spectra.  Mineral recovered from the defect region of empty 




Samples for mechanical testing were explanted and wrapped in PBS-soaked gauze 
and frozen at -20oC until use.  Mechanical testing was performed as previously described 
(Oest et al. 2007).  Briefly, samples were thawed in room temperature PBS and most of 
the soft tissue was removed, taking care not to mechanically disrupt tissue in the defect 
site.  The ends of each bone were potted in Wood’s metal up to the polysulfone plate and 
secured with pins into potting blocks.  Blocks were loaded onto an ElectroForce® 
mechanical testing machine (Elf 3200 by Bose) and the polysulfone plate was removed 
just before testing.  Samples were loaded in torsion at a displacement rate of 3o/s up to 
360o.  Maximum torque before failure was recorded for each sample. 
Statistical Analysis 
 Data from two independent studies was pooled, and a mixed model ANOVA was 
used to define experiment and individual animal as sources of error.  This analysis was 
performed using the Hierarchical Linear Mixed Models function in Systat v12, which 
uses a Satterthwaite approximation to account for differences in sample sizes.  A p-value 
< 0.05 was considered significant.  
Results 
Runx2 expression and cell viability 
 To measure transduction efficiency of the Runx2 and empty-vector retroviruses, 
eGFP expression was measured via flow cytometry.  Unmodified cells were used as a 
control population, and transduction efficiency of retrovirus-transduced cells was 
determined using the 2% of background method (Overton 1988). Runx2-modified cells 
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showed 40% transduction efficiency as measured by eGFP expression compared to 
control cells (Figure  4.2B).  Empty vector-transduced cells showed 60% transduction 
efficiency (data not shown). 
 
 
Figure  4.2.  Runx2-modified BMSCs show high eGFP expression at 3 days post-transduction 
and are viable on PCL scaffolds containing lyophilized collagen mesh.  (A) Diagram of Runx2 
plasmid showing internal ribosomal entry site (IRES) for eGFP expression.  (B) Flow cytometric 
detection of eGFP expression in unmodified and Runx2-modified BMSCs.  Transduction 
efficiency of Runx2-modified cells (arrow) is 40% compared to unmodified controls.  (C) Cross-
sectional microCT image of a PCL scaffold.  (D) Confocal live/dead images of unmodified and 
Runx2-modified BMSCs on PCL scaffolds with and without collagen meshes.  Live cells are 
shown in green and dead cells in red.  Scale bar is 200 µm.  Cells populate the pore volume of 
the PCL in (C) by adhering to collagen meshes lyophilized inside the scaffold. 
 
PCL scaffolds without collagen meshes were analyzed by microCT to determine 
average pore volume and pore size (Figure  4.2C).  Live/Dead staining of cells on 
scaffolds 3 days post-seeding shows unmodified and Runx2-modified BMSCs are viable 
on PCL scaffolds both with and without collagen meshes.  Scaffolds with collagen 
meshes promote an even distribution of cells throughout the pore volume of the PCL 
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while scaffolds without meshes do not retain cells in the pore volume (Figure  4.2D).  
PCL scaffolds with collagen meshes were subsequently used for all in vivo studies. 
Radiography and MicroCT Analysis 
 Immediately following surgery, animals were monitored several times daily for 
signs of pain or stress, regular eating habits, and normal ambulation.  Within one week 
following surgery, signs of stress were minimal, regular eating had returned and normal 
ambulation using both hind limbs was restored.   
To monitor bone formation in critically-sized defects, animals were anesthetized 
every 4 weeks and defects were scanned via X-ray and microCT.  X-ray images show 
gross morphological changes in bone growth at the defect site over time.  While empty 
defects, PCL and BMSC groups showed minimal bone formation, Runx2 showed 
substantial increases in bone growth over time (Figure  4.3).  Representative X-ray images 
from each group are shown in Figure  4.3A, and the corresponding three-dimensional 
microCT reconstructions at 12 weeks are shown in Figure  4.3B.  No differences were 
observed between BMSC and empty vector groups (data not shown). 
At 4, 8 and 12 weeks post-surgery, bone volume in all defects was quantified via 
microCT.  Negligible bone formation occurred at the ends of host bone in empty defects 
and PCL defects.  However, bone formation in BMSC and Runx2 defects increased over 
time.  At 4 and 8 weeks post-surgery, Runx2 defects contained significantly more bone 
than unmodified BMSC defects (p < 0.05, n=8). At 12 weeks, bone volume in Runx2 
defects was not significantly different compared to unmodified BMSC defects (p = 
0.059) (Figure  4.3C).  This differential time course of bone formation in BMSC and 
Runx2 defects indicates that Runx2-modified BMSCs initially accelerate bone formation 
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in critically-sized defects but that the inherent osteogenic capacity of unmodified BMSCs 






Figure  4.3.  Runx2-modified BMSCs accelerate bone formation in critically-sized defects compared to 
unmodified BMSCs. (A) X-ray images showing representative images for each group.  (B) MicroCT 
images showing the same samples from (A).  (C) Bone volume is significantly greater in Runx2-treated 
defects compared to BMSC-treated defects at 4 and 8 weeks (* p < 0.05).  At 12 weeks, bone formation due 
to unmodified BMSCs is not significantly different from Runx2-modified cells (p=0.059), indicating that 





 To more fully characterize areas of high attenuation imaged by microCT, one 
sample from the Runx2 defect group was subjected to histological analysis at 12 weeks.  
Prior to embedding, the sample was scanned via microCT and thresholded in the same 
manner as all other samples.  Then, Sanderson’s Rapid Bone StainTM, which 
distinguishes areas of mineralized bone from demineralized connective tissue and 
osteoid, was applied to the sample revealing mineralized bone tissue in a red/pink color 
and demineralized osteoid in blue/green (Sanderson and Bachus 1997).  Because this 
sample underwent both Sanderson’s stain and microCT scanning, matching slices from 
histology and microCT were compared.  This analysis shows that areas of high 
attenuation that were thresholded in microCT and used as a measure of bone volume in 
Figure 4.3, directly match areas of red/pink staining defined as mineralized bone tissue in 
the Sanderson’s stain (Figure  4.4). 
 
Figure  4.4.  Histological analysis confirms that areas of high attenuation revealed by microCT are bone.   
(A) Sanderson’s rapid bone stain for a Runx2-modified BMSC sample showing bone in red/orange and soft 
tissue in blue/green. (B) A corresponding 2D microCT slice from the same sample, thresholded to isolate 





 To determine the composition of bone formed in all defects, samples of bone 
taken from the defect area in all groups were analyzed via FTIR analysis.  Spectra from 
native bone contains all peaks expected for biologic apatite, including amide peaks for 
protein at 1700 and 1550 cm-1, a small carbonate peak at 900 cm-1, a broad phosphate 
peak for stretching vibrations at 900 – 1200 cm-1, and a phosphate doublet for bending 
vibrations at 525 – 625 cm-1 (Paschalis et al. 1997; Bonewald et al. 2003; Byers and 
García 2004).  Cell-loaded samples having either unmodified BMSCs or Runx2-modified 
BMSCs displayed all of these expected peaks (Figure  4.5), indicating that the mineralized 
tissue in these defects was a biological, poorly crystalline hydroxyapatite.  Cell-free PCL 
scaffolds containing lyophilized collagen also displayed all expected peaks for native 
bone; however, CO3 and PO4 (bending) peaks were less prominent in these cell-free 
samples as compared to native control bone or cell-loaded samples.  Finally, empty 
defect negative controls showed amide peaks and some phosphate deposits; however, 
CO3 peaks and prominent PO4 (stretching) peaks were not present, indicating that the 





Figure  4.5.  FTIR spectra demonstrate that the structural composition of 
cell-mediated bone formation is similar to that of native bone.  Bands 
characteristic of biologic hydroxyapatite, namely a small carbonate peak at 
855 – 890 cm-1, a broad phosphate peak at 900 – 1200 cm-1, and a 
phosphate doublet at 525 – 625 cm-1, are present in Runx2-modified and 
unmodified BMSC-treated defects, as well as native bone.  Cell-free 
scaffold spectra contain peaks that are shifted compared to native bone, and 
empty defects do not contain characteristic peaks. 
 
Mechanical strength of repaired defects is dependent on bridging 
 To assess mechanical functionality of new bone present in critically-sized defects, 
femurs were harvested 12 weeks post-surgery and subjected to postmortem torsional 
testing. Although microCT revealed differences in bone volume between BMSC and 
Runx2 defects at 4 and 8 weeks, maximum torque sustained at 12 weeks was not 
significantly different between these two groups (Figure  4.6A).  Stiffness and work to 
failure were also evaluated and no significant differences among experimental groups 
were observed (data not shown).  We hypothesized that mechanical strength is dependent 
on defect bridging.  Whereas some samples contain a large amount of bone in the defect 
site, high levels of mechanical strength are only present when this bone is firmly attached 
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to both the proximal and distal end of the host bone.  Without full attachment (i.e. 
complete bridging) samples that have large bone volumes sustain low torque loads. 
 To demonstrate that mechanical strength is dependent on defect bridging, X-ray 
images for all samples were blindly assessed for their extent of bridging and assigned a 
bridging score from 0-5 based on the criteria outlined in Figure  4.6B, where 0 is no bone 
in the defect and 5 is a fully bridged defect.  Representative X-ray images for each score 
are shown in Figure  4.6C.  By looking at bone volume versus maximum torque for each 
sample grouped by briding scores, a trend is observed where samples with higher 
bridging scores generally have greater max torque (Figure  4.6D).  Although there are no 
significant differences in torsional strength between BMSC and Runx2 defects, a 
distribution of bridging scores from each group shows that Runx2-modified defect scores 
are shifted towards fully bridged or nearly fully bridged (scores 4 and 5) compared to 
unmodified BMSC scores (Figure  4.6E).  A Kruskall Wallis one way ANOVA by ranks 





Figure  4.6.  Mechanical properties of repaired segmental defects.  (A) Despite differences in bone volume 
between Runx2-treated and BMSC-treated defects, maximum torque is not significantly different.  (B) 
Criteria for bridging scores assigned to each sample.  (C) Representative faxitron images of scores 
described in (B).  (D) Samples with higher bridging scores are shifted to the upper right of a bone volume 
versus maximum torque correlation graph.  (E) The distribution of bridging scores for Runx2-treated 





 This study examined the effects of treating critically-sized segmental defects in 
rat femurs with cell/scaffold constructs containing Runx2-modified BMSCs.  In 
comparison to unmodified BMSCs on scaffolds, scaffolds alone, or empty defects, we 
demonstrate that bone healing in rat femurs is accelerated by treatment with Runx2-
modified BMSCs.  At both 4 and 8 weeks post-surgery, quantitative microCT analysis 
showed significantly more bone formation in defects treated with Runx2-modified 
BMSCs versus unmodified BMSCs, indicating accelerated healing due to Runx2 
treatment at early time points.  However, at 12 weeks post-surgery, no statistical 
differences in bone formation between unmodified and Runx2-modified BMSCs were 
present, highlighting the inherent osteogenic capabilities of this cell type.  Taken 
together, this study presents an accelerated method of tissue engineering for healing large 
bone defects in vivo. 
 Runx2 has been described as a molecular switch for osteoblast biology (Ducy 
2000), yet few studies have examined the potential use of Runx2 in healing critically-
sized bone defects.  Three previous orthotopic analyses of Runx2-modified BMSCs have 
been performed and each one focused on healing critically-sized calvarial defects (Zheng 
et al. 2004; Byers et al. 2006; Zhao et al. 2007).  Although the cranial defect model 
provides relevant information regarding the healing of craniofacial defects, conflicting 
evidence regarding the role of periosteum, dura mater, and surrounding healthy bone 
tissue in cranial defect healing makes separation of host response from treatment effect 
difficult in this model (Aalami et al. 2003).  In particular, dura mater has been shown to 
have a significant effect on cranial defect healing (Ozerdem et al. 2003).  To our 
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knowledge, no other study to date has examined the use of Runx2 as a gene therapy 
strategy for the healing of critically-sized segmental defects in long bones.  The present 
study examined Runx2 treatment in a segmental defect model, where contributions from 
the dura mater, which are irrelevant to anatomical locations other than the calvaria, are 
not present, making this a more rigorous test bed for the healing of large bone defects. 
 In addition to differences in anatomical location between this study and other 
orthotopic studies of Runx2, factors such as species, time points, and scaffold types also 
varied between the studies.  Zheng et al. implanted adenovirally transduced Runx2-
BMSCs on collagen sponges for 4 weeks in BALB/c mice.  Using manual segmentation 
of radiographic images, they found significantly more bone in defects treated with Runx2 
transduced cells over unmodified cells, cell-free scaffolds and empty defects (Zheng et al. 
2004).  Zhao et al. used adenoviral transduction to deliver Runx2 and LacZ (control) to 
BMSCs.  Cells were implanted on gelatin sponges for 7 weeks in C57BL6 mice, and CT 
quantification showed more bone in defects treated with Runx2 over LacZ.  However, no 
cell-free or empty defect controls were included in this study (Zhao et al. 2007).  Our 
group has also previously reported on Runx2 treatment of cranial defects.  We have 
investigated BMSCs retrovirally tranduced with Runx2 and implanted on PCL scaffolds 
for 4 weeks in the rat calvarium.  MicroCT analysis showed more bone in Runx2 treated 
defects, compared to unmodified controls and empty defects, following a 21 day pre-
culture period.  However, due to the open pore structure of our PCL scaffolds, cell-free 
scaffolds performed as well as Runx2-engineered cell-loaded scaffolds in this study 
(Byers et al. 2006).  Given these differences, all 3 previous orthotopic studies comparing 
Runx2 transduced BMSCs to unmodified or LacZ transduced BMSCs showed a 
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significant increase in bone formation due to Runx2 treatment, in agreement with the 
present study. 
 Although Runx2-modified BMSCs accelerated bone repair in critically-sized 
defects in this study, unmodified BMSCs eventually produced equivalent amounts of 
bone, pointing to the inherent ability of BMSCs to mineralize bone defects.  Many studies 
have demonstrated successful healing of bone defects using unmodified BMSCs in pre-
clinical trials (Bruder et al. 1998; Kon et al. 2000; Petite et al. 2000), and recently, a pilot 
study of the implantation of autologous human BMSCs for repair of large bone defects in 
humans was reported by Marcacci et al. 2007.  In this study, 4 patients presented with 
large bone diaphysis defects, for which previous treatment with conventional surgical 
therapies had failed.  Each patient underwent a BMSC harvest from the iliac crest, and 
the isolated cells were then cultured and seeded onto hydroxyapatite scaffolds custom 
made to fit the size and shape of the defects.  For patients 1, 2, and 4, complete 
consolidation between the implant and host bone was radiographically evident between 
5-7 months post-surgery, at which time external fixation devices were removed.  For 
these patients, limb function was gradually regained within 8 months post-surgery.  For 
patient 3, whose injury was more complex and involved the elbow joint, a custom made 
cast was fitted over the defect after removal of the Ilizarov apparatus at 8 months post-
surgery.  This patient recovered limb function after 16-24 months post-surgery.  For all 
patients, a 6-7 year follow-up revealed that stable bone-implant integration was 
maintained (Marcacci et al. 2007).  The success of this study makes treatment with 
autologous BMSCs an attractive option for patients with large bone defects.  However, a 
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reduction in the time needed for external fixation is desirable, making the accelerated 
healing strategy presented in the current study relevant for clinical application. 
 The success of unmodified BMSCs for healing critically-sized defects in other 
pre-clinical studies may largely depend on the scaffold type used to deliver the cells.  For 
example, all of the aforementioned studies which demonstrate successful healing (i.e. 
complete bridging) of segmental defects when treated with unmodified BMSCs employed 
the use of a hydroxyapatite scaffold to deliver the cells to the defect site.  The 
osteoconductive properties of hydroxyapatite have been reviewed elsewhere (LeGeros 
2002).  In brief, calcium phosphate ceramics demonstrate bioactivity and 
osteoconductivity leading to rapid and strong osseointegration with host bone tissue when 
implanted into an orthotopic site.  In fact, implantation of HA alone (without cells) has 
been shown to heal osteotomy defects in human patients (Meyer et al. 2007).  In the 
current study, the use of a polymer scaffold, which is not osteoconductive by itself, in 
combination with the rigorous 8mm segmental defect test bed, may explain why defects 
treated with unmodified BMSCs resulted in non-union after 12 weeks.  This result is in 
agreement with other studies that also show non-union of segmental defects treated with 
unmodified BMSCs when a non-ceramic scaffold is the delivery vehicle (Turgeman et al. 
2001; Fialkov et al. 2003).  Recent evidence suggests that the modification of synthetic 
PCL scaffolds with hydroxyapatite nanoparticles increases the bone forming response of 
cells seeded on the scaffolds (Wutticharoenmongkol et al. 2007).  In this study, the 
rationale behind including a collagen matrix within PCL scaffolds was to increase the 
therapeutic load of cells delivered the defect site.  It is possible that incorporation of an 
osteoconductive material into our scaffolds would further enhance the cellular response.  
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However, in this study, the use of a collagen-PCL scaffold, which did not heal defects in 
the cell-free condition, allowed us to demonstrate the effect of Runx2 treatment without 
contributions from the scaffold. 
 A distinct advantage of this study over many reports of segmental defect healing 
is the use of mechanical testing to assess functionality of the defects.  A large majority of 
studies that report successful healing of bone defects rely solely on a combination of X-
ray analysis and histological evaluation as a measure of defect healing.  However, this 
approach does not provide functional information, which is necessary to fully evaluate 
the success of a given treatment strategy for bone healing (Liebschner 2004).  Few 
groups report mechanical testing analysis, but of those that do, the most common test 
methods are torsion (Cook et al. 1994; Cook et al. 1994; Cook et al. 1995; Hsu et al. 
2007; Oest et al. 2007; Rai et al. 2007).  The current study demonstrates the importance 
of including mechanical testing analysis in any bone healing study because, in this case, 
the significant differences in bone volume measured by microCT did not translate to 
significant differences in torsional strength between Runx2 and BMSC treated defects.  
However, we did observe differences in torsional strength between fully bridged samples 
compared to non-unions.  This result is in agreement with a mounting body of work 
suggesting that greater bone mass will not necessarily result in greater bone strength.  For 
example, recent evidence suggests that patients with a high level of bone turnover may be 
at higher risk for bone fracture regardless of bone mineral density (Hernandez 2008). 
This concept is known as bone quality, a term used to describe any skeletal aspect of 
bone, excluding bone mass (i.e. bone shape, size, trabecular connectivity, etc) that affects 
its strength (Hernandez and Keaveny 2006).  In the present study, although significant 
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increases in bone mass were observed due to Runx2 treatment, bone quality was not 
affected.  The implication of these results is that radiographic and histological methods of 
evaluating bone tissue are not sufficient to fully characterize the extent of bone defect 
healing.  Functional mechanical evaluation of bone defects should be used in conjunction 
with other methods for complete analysis of both bone mass and bone quality. 
 In summary, we have demonstrated accelerated bone healing in critically-sized 
defects in rat femurs due to treatment with Runx2-modified BMSCs delivered on 
synthetic polymer scaffolds.  This strategy targets a specific osteoblastic signaling 
pathway to upregulate osteoblastic differentiation of BMSCs to promote bone formation, 
and may shorten the long time scale required for complete healing of defects with 
unmodified BMSCs.  Further investigation into increasing functional strength is 
warranted.  With further development, this gene therapy technique could be a useful 
strategy for healing large bone defects in humans. 
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SIMPLE COLLAGEN-MIMETIC SURFACE MODIFICATION 
INCREASES BONE FORMATION IN CRITICALLY-SIZED 
RODENT FEMORAL DEFECTS 
 
Introduction 
 Limitations with current clinical bone grafting procedures, namely autografts and 
allografts, have led to the development of alternative methods of bone defect healing via 
regenerative medicine strategies (Hutmacher and García 2005; Awad et al. 2007; 
Cancedda et al. 2007).  Most tissue engineering strategies can be broadly categorized as 
osteoinductive or osteoconductive, whereby a tissue engineering construct stimulates 
differentiation of host cells to subsequently form bone or promotes attachment of bone 
forming cells, respectively (De Long et al. 2007).  The first well documented study of 
bone formation by osteoinduction was described by Marshall Urist in 1965 by the 
implantation of demineralized bone matrices into ectopic sites in rabbits and rodents 
(Urist 1965).  From this experiment came the discovery and characterization of bone 
morphogenetic proteins (BMPs), soluble growth factors that work through Smad-
dependent signaling pathways to promote osteoblastic differentiation (Derynck and 
Zhang 2003).  More than 15 individual BMPs have now been identified and several 
studies have shown that BMP-2 and BMP-7 promote healing of critically-sized bone 
defects in both small and large animals (Yasko et al. 1992; Cook et al. 1994; Cook et al. 
1994; Cook et al. 1995) and in humans (Govender et al. 2002).  Additionally, BMP-7 is 
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currently FDA-approved for human use in long bone non-unions where autograft 
treatment is not feasible or has failed, and BMP-2 is available for clinical use in the 
treatment of open tibial fractures and for lumbar spinal fusion (Boden 2005; Bishop and 
Einhorn 2007). 
 Although the use of BMPs in clinical repair of bone defects has demonstrated 
success, several factors contribute to the continued search for regenerative medicine 
alternatives.  First, the residence time of BMP in a defect site following localized delivery 
directly affects its osteogenic potential.  As a soluble factor, diffusion of BMP away from 
the delivery site decreases the amount of bone formed in an implant (Uludag et al. 2000).  
Efforts are being made to increase BMP residence time at the defect site, by the 
immobilization of BMP onto implants (Yamachika et al. 2009).  Second, the dosage of 
BMPs required to stimulate bone formation in large bone defects in humans far exceeds 
the successful working dosage described in preclinical trials.  Thus, production of enough 
recombinant protein for one vial of BMP for human use is a very costly procedure (Alt 
and Heissel 2006; Bishop and Einhorn 2007; Cancedda et al. 2007).  Clinical bone 
healing would benefit from a more targeted and cost effective solution. 
 Recently, the use of biomimetic strategies which attempt to recapitulate the 
environment of the bone ECM have been used to promote osseointegration and bone 
formation in vivo (Hubbell 2003).  Short immobilized peptide sequences and fragments 
derived from ECM proteins, such as the RGD sequence from fibronectin, have been used 
to promote cell attachment to titanium implants as an improved method of implant 
fixation and osseointegration (Ferris et al. 1999; Bernhardt et al. 2005; Elmengaard et al. 
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2005; Reyes et al. 2007; Petrie et al. 2008). These strategies take advantage of the 
specific interactions between ECM protein ligands and integrin cell surface receptors. 
 The integrin receptors play a crucial role in cell attachment and ECM-mediated 
cell signaling.  Integrin dimers, consisting of one α and one β subunit, bind to specific 
sites contained within ECM proteins, thereby promoting cell attachment, migration, 
mechanotransduction, differentiation, and numerous other cell functions (Clark and 
Brugge 1995; Hynes 2002).  In particular, type I collagen-mediated activation of the α2β1 
integrin receptor promotes osteoblastic differentiation of bone marrow stromal cells 
(BMSCs) and pre-osteoblastic cells in vitro leading to the production of mineralized 
matrices on 2-dimensional surfaces (Jikko et al. 1999; Mizuno et al. 2000).  The α2β1 
receptor is highly expressed on the surface of osteoblastic cells (Gronthos et al. 1997), 
and it binds specifically to the triple helical hexapeptide domain, GFOGER, contained 
within collagen I (Knight et al. 2000).  We have previously demonstrated that isolation of 
this active binding sequence, GFOGER, via synthetic fabrication of a triple helical 
GFOGER peptide, allows engineered control over osteoblastic differentiation of cells on 
GFOGER coated 2D surfaces (Reyes and García 2003; Reyes and García 2004).  
Furthermore, use of GFOGER as an implant coating for titanium tibial plugs enhances 
osseointegration in vivo to levels greater than that of unmodified titanium or titanium 
coated with full length collagen I (Reyes et al. 2007).  This collagen mimetic strategy for 
osseointegration specifically targets osteoblastic cells through α2β1-mediated signaling 
by eliminating extraneous binding sites contained in the full length protein.  Furthermore, 
the synthetically derived peptide is inexpensive, easy to fabricate and poses no risk of 
disease transmission.  
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 In this study, we examined the effects of GFOGER surface modification on the 
healing of critically-sized bone defects in rats.  We hypothesized that the specific 
targeting of α2β1 receptors in orthotopic segmental bone defects via GFOGER-coated 
polymer scaffolds would increase bone formation in critically-sized defects compared to 
uncoated scaffolds.  The fabrication of synthetic peptide sequences provides an 
inexpensive alternative to costly methods of bone tissue engineering, such as those 
employing BMPs or using cells.  This simple surface modification strategy, which 
imparts specific biologic functionality to synthetic implants represents an elegant yet 
facile procedure for future clinical bone healing. 
Materials and Methods 
GFOGER synthesis 
 The synthetic peptide GGYGGGPC(GPP)5GFOGER(GPP)5GPC, where O is 
hydroxyproline, was fabricated by the Emory University Microchemical Facility using 
stepwise solid-phase procedures, as previously described (Reyes and García 2003).  This 
peptide has a triple helical conformation (Figure  5.1A), which mimics the structure of 
collagen I and is essential for peptide bioactivity (Knight et al. 2000).  The purified 
peptide was stored as a TFA salt at -20oC.  For short term storage, the peptide was 
reconstituted to 10 mg/mL in 0.1% TFA and 0.01% sodium azide and stored at 4oC.  For 






Figure  5.1.  The synthetic peptide fragment, GFOGER, is passively adsorbed to PCL scaffolds and 
saturates the surface. (A) Space filling model of the GFOGER molecule shows its triple helical, collagen 
mimetic conformation.  (B) MicroCT is used to characterize the structure of PCL scaffolds.  Scaffold 
parameters for the first in vivo study are listed. (C) GFOGER surface saturation on PCL scaffolds occurs at 
a coating concentration of 20 µg/mL. Biotinylated GFOGER was adsorbed onto PCL scaffolds and 
detected via ELISA. Error bars represent standard deviation, n=3. 
 
PCL scaffold fabrication and coating with GFOGER 
 Polycaprolactone (PCL) scaffolds were produced in sheets 9 mm thick by fused 
deposition modeling as previously described (Zein et al. 2002).  Sheets were cut into 
scaffolds using a 4 mm diameter dermal biopsy punch (Miltex), and microCT analysis 
was used to characterize the structural parameters of the scaffolds (Figure  5.1B).  For the 
first in vivo study, scaffold pore volume was 73% of the total volume, and pore size was 
560 µm.  
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 For passive adsorption of GFOGER onto PCL scaffold surfaces, scaffolds were 
cleaned in 70% ethanol for 30 minutes, rinsed in sterile ddH2O 3 times, then soaked in 
PBS for 10 minutes prior to peptide coating.  For in vivo studies, an additional step was 
added for endotoxin removal, which involving rinsing scaffolds in 70% ethanol for 4 
days on a shaker plate with daily ethanol replacement.  To coat with GFOGER, scaffolds 
were removed from PBS, wicked on Kimwipes, and then added to a solution of 50 µg/mL 
of GFOGER in PBS for 2 hours at room temperature.  Uncoated scaffolds received the 
same treatment, but were kept in PBS without GFOGER.  Prior to implantation, scaffolds 
were rinsed briefly in PBS to remove any unbound peptide. 
Biotinylation and detection of GFOGER peptide 
 The carboxyl end of the GFOGER peptide was biotinylated using an EZ-Link® 
Amine-PEG3-Biotin kit (Pierce Biotechnology) to allow detection of the peptide after 
adsorption onto PCL scaffolds.  Briefly, reconstituted GFOGER peptide was added to 
MES buffer, mixed with Amine-PEG-Biotin solution and EDC according to 
manufacturer’s instructions, then incubated with shaking for 3.5 hours at room 
temperature.  Unreacted biotin was removed via dialysis overnight into PBS using a 
Slide-A-Lyzer Dialysis Cassette with a molecular weight cut off of 3500 (Thermo 
Scientific).  After dialysis, protein concentration was measured using a BCA Protein 
Assay kit (Pierce Biotechnology). 
For in vitro detection of biotinylated GFOGER on PCL scaffolds, a modified 
ELISA against biotin was performed.  Briefly, scaffolds were coated with biotinylated 
GFOGER, rinsed thoroughly in PBS, wicked on Kimwipes, then blocked in 0.25% heat 
denatured BSA with 0.0005% Tween 20, 1 mM EDTA, and 0.025% NaN3 in PBS for 1 
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hour at 37oC.  After blocking, scaffolds were rinsed rigorously in PBS, incubated in a 
1:2000 dilution of anti-biotin antibody conjugated to alkaline phosphatase (clone BN-34, 
Sigma) for 1 hour at 37oC, rinsed again rigorously, then incubated with 60µg/mL of 4-
methylumbelliferyl phosphate (MUP) substrate in diethanolamine buffer (pH 9.5) for 1 
hour at 37oC.  Fluorescent signal was measured by transferring 100 µL from each 
scaffold to the well of a u-bottom black plate and reading excitation/emission spectra at 
360/465 nm on a HTS 7000 Plus Bio Assay Reader (Perkin Elmer).  Uncoated PCL 
scaffolds served as negative controls and were incubated in PBS without GFOGER, then 
rinsed and blocked following the same procedure as GFOGER-coated scaffolds.  
Substrate-only negative controls were coated with GFOGER but excluded use of the anti-
biotin antibody. 
Segmental Defect Surgery 
Femoral defects were created bilaterally as previously described (Oest et al. 
2007).  Briefly, 13 to 15 week old female Lewis rats were anesthetized using isoflurane, 
and the hind limbs were shaved and swabbed with cycloheximide and alcohol to prepare 
the skin for incision.  An anterolateral incision was made from the hip to the knee to 
allow blunt separation of the quadriceps muscles, exposing the femur (Figure  5.2A).  
Before the defect was created, a modular fixation device was attached to the bone for 
mechanical support.  The device consisted of two stainless steel plates affixed directly to 
the bone via screws and one polysulfone plate, which spanned the defect and was 
attached to the stainless steel plates (Figure  5.2B).  Use of this modular system was 
advantageous for postmortem mechanical testing and non-invasive in vivo X-ray and 
microCT analysis.  After attachment of the fixation device, an 8.0 mm segment of bone 
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was removed via bone saw with irrigation, and a scaffold was press fit into the defect 
(Figure  5.2A).  Notches in the polysulfone plate, spaced 8.0 mm apart, ensured each 
defect was consistently created the same length (Figure  5.2B).  Muscle was closed around 




Figure  5.2.  Surgical procedure for critically-sized segmental defects in rat femurs.  (A) Each defect is 
stabilized by a fixation plate. (i) Blunt dissection of the quadriceps exposes the femur and enables 
placement of the fixation plate.  (ii) An 8.0 mm segment is removed from the femur via bone saw, and (iii) 
scaffolds are press fit into the defect.  (B) An explanted femur shows the modular fixation plate attached to 
the bone via stainless steel screws.  Notches in the polysulfone plate (marked with arrows) are spaced 8mm 
apart ensuring each defect is created at the same size. 
 
For in vivo studies, the following 3 groups were tested: (i) uncoated PCL 
scaffolds, (ii) GFOGER-coated PCL scaffolds and (iii) empty defect control.  For the 
empty defect group, the surgical procedure remained the same, but no scaffold was 
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placed in the defect.  A coating concentration of 50 µg/mL was used for all implanted 
GFOGER-coated scaffolds.  
 Following surgery, animals were given 3 daily doses of buprenorphine at 0.03 
mg/kg for 2 consecutive days and 3 doses of 0.01 mg/kg on the third day to control pain. 
Animals were monitored daily for signs of pain and distress, progress of wound closure, 
regular eating habits and normal ambulation.  A small percentage (< 8%) of rats 
developed infections in or around the surgery site, or experienced mechanical failure of 
the fixation device.  These animals were removed from the study and euthanatized, and 
any data collected from these animals was excluded.  Two weeks post surgery, skin 
wounds were completely healed, and animals were anesthetized with isoflurane for 
removal of wound clips.  At 4, 8 and 12 weeks post-surgery, animals were anesthetized 
with isoflurane and the hind legs were scanned via radiography and microCT as 
described below.  Twelve weeks post-surgery, animals were euthanized by CO2 
inhalation, and the femurs, along with surrounding muscle tissue, were harvested for 
postmortem microCT evaluation, histology and mechanical testing.  
Radiography and MicroCT Analysis 
Every 4 weeks following surgery, 2-dimensional X-ray images of each femur 
were non-invasively obtained using an MX-20 Specimen Radiography System (Faxitron 
X-ray Corporation) to make gross morphological observations of bone formation in each 
defect site.   To obtain X-ray images, animals were anesthetized in a gas chamber filled 
with 5% isoflurane and maintained under anesthesia using 2% isoflurane flow into a face 
mask.  Each hind leg of anesthetized animals was scanned for 15 s with a X-ray beam 
energy of 23 kV. 
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 In addition to radiographic imaging, samples were non-invasively analyzed every 
4 weeks post-surgery by microCT using a vivaCT 40 (Scanco Medical) to quantify bone 
volume in each defect site.  For microCT, animals were anesthetized in the same manner 
as described above for radiography and placed in a rodent holder with one leg 
outstretched for scanning.  The defect area in between the stainless steel plates of the 
fixation device was imaged with a X-ray beam energy of 55 kVp and intensity of 109 µA, 
and the integration time was 200 ms.  Scanning resolution was 38 µm.  After imaging 
was complete, noise was reduced from 3-dimensional reconstructions of each scan by 
applying a Gaussian filter (sigma=1.2, support=2) using the Scanco Medical µCT 
Evaluation Program.  Images were thresholded at 270 mg HA/ccm to isolate mature bone 
from soft tissue and the polymer scaffold and fixation plate.  Bone volume was quantified 
using directly computed values. 
Histological Analysis 
 Immediately following euthanasia, samples for histological analysis were fixed in 
10% neutral buffered formalin.  One day after fixation, soft tissue was removed, and 
specimens were placed in fresh formalin.  Prior to embedding, fixed tissues were scanned 
ex vivo via microCT as described above to allow matching of histological sections with 
microCT slices.  After scanning, specimens were dehydrated in a series of alcohols, 
cleared in xylene, and embedded in methyl methacrylate (MMA).  Ground sections, 50-
80 µm thick, were prepared by Wasatch Histo Consultants, Inc. (Winnemucca, NV) and 
stained using Sanderson’s Rapid Bone StainTM and a van Gieson counterstain (Reyes et 
al. 2007).  Stained histological sections were then matched to thresholded microCT scans 




Explanted samples for mechanical testing were wrapped in PBS-soaked gauze and 
frozen at -20oC until use.  Mechanical testing was performed as previously described 
(Oest et al. 2007).  Briefly, samples were thawed in room temperature PBS and most of 
the soft tissue was removed, leaving some soft tissue surrounding each defect and taking 
care not to mechanically disrupt tissue in the defect site.  The ends of each bone were 
potted in Wood’s metal up to the polysulfone plate and secured with pins into potting 
blocks.  Blocks were loaded onto an ElectroForce® mechanical testing machine (Elf 
3200, Bose) and the polysulfone plate was removed just before testing.  Samples were 
loaded in torsion at a displacement rate of 3o/s up to 360o.  Maximum torque before 
failure was recorded for each sample.  Stiffness and work to failure were calculated. 
Statistical Analysis 
 Data was analyzed using ANOVA in Systat v11.  Samples identified as statistical 
outliers that also met additional criteria for removal, such as improper plate placement, 
were removed from analysis.  A p-value < 0.05 was considered significant.  
Results 
Saturation of GFOGER on PCL scaffolds 
 To determine a coating concentration for GFOGER saturation on PCL scaffolds, 
varying concentrations of biotinylated GFOGER were adsorbed onto PCL scaffolds in 
vitro and a saturation curve was generated via ELISA for anti-biotin.  Figure  5.1C shows 
that GFOGER saturates the surface of PCL scaffolds at a coating concentration of 20 
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µg/mL.  For all in vivo studies, GFOGER was used at a coating concentration of 50 
µg/mL to ensure saturation of GFOGER on PCL scaffold surfaces. 
Bone formation in critically-sized defects 
 Immediately following surgery, animals were monitored several times daily for 
signs of pain or stress, regular eating habits, and normal ambulation.  Within one week 
following surgery, signs of stress were minimal, regular eating had returned and normal 
ambulation using both hind limbs was restored.  
To monitor bone formation in critically sized defects, x-ray and microCT scans 
were performed every 4 weeks post surgery.  X-ray images show gross morphological 
changes in bone growth at the defect site over time.  While empty defects and uncoated 
PCL-treated defects showed minimal bone formation, GFOGER-treated defects showed 
substantial increases in bone growth over time.  Representative X-ray images from each 
group are shown in Figure  5.3A, and the corresponding three-dimensional microCT 
reconstructions at 12 weeks are shown in Figure  5.3B. 
At 4 and 12 weeks post-surgery, animals were anesthetized and bone volume in 
all defects was quantified via microCT.  Negligible bone formation occurred at the ends 
of host bone in empty defects and uncoated PCL defects.  However, bone formation in 
GFOGER defects was significantly greater compared to PCL and empty defects (Figure 
 5.3C).  These indicate that specific targeting of the α2β1 integrin via GFOGER surface 







Figure  5.3.  GFOGER-coated scaffolds significantly enhance bone formation in critically-sized defects 
compared to uncoated scaffolds and empty defect controls.  (A) Faxitron images show that empty defects 
do not heal after 12 weeks, and negligible bone formation is present in uncoated PCL-treated defects.  
However, GFOGER-treated defects promote bone formation as early as 4 weeks.  Representative samples 
are shown for each group. (B) MicroCT images show the same samples from (A) at 12 weeks.  (C) Bone 
volume is significantly greater in GFOGER-treated samples at both 4 and 12 weeks compared to empty 
defects and uncoated PCL-treated samples.  Error bars represent standard error of the mean. n=8 and n=9 
for PCL and GFOGER at 4 weeks, respectively.  n=7 and n=8 for PCL and GFOGER at 12 weeks, 





 To more fully characterize areas of high attenuation imaged by microCT, one 
sample from the GFOGER group was subjected to histological analysis at 12 weeks.  
Prior to embedding, the sample was scanned via microCT and thresholded in the same 
manner as all other samples.  Then, Sanderson’s Rapid Bone StainTM, which 
distinguishes areas of mineralized bone from demineralized connective tissue and 
osteoid, was applied to the sample revealing mineralized bone tissue in a red/pink color 
and demineralized osteoid in blue/green (Sanderson and Bachus 1997).  Because this 
sample underwent both Sanderson’s stain and microCT scanning, matching slices from 
histology and microCT were compared.  This analysis shows that areas of high 
attenuation that were thresholded in microCT and used as a measure of bone volume in 
Figure 5.3, directly match areas of red/pink staining defined as mineralized bone tissue in 
the Sanderson’s stain (Figure  5.4). 
 
 
Figure  5.4.  Histological analysis confirms that areas of high attenuation revealed by microCT are 
bone.  (A) Sanderson’s rapid bone stain for a GFOGER-coated sample showing bone in red/orange 
and soft tissue in blue/green. (B) Two-dimensional microCT image from the same sample as (A) 




Mechanical strength of repaired defects is dependent on bridging 
 To assess functionality of new bone present in critically-sized defects, femurs 
were harvested 12 weeks post-surgery and subjected to postmortem torsional testing. 
Although microCT reveals differences in bone volume between GFOGER-treated and 
PCL-treated defects, maximum torque sustained was not significantly different between 
these two groups (Figure  5.5A).  Stiffness and work to failure were also evaluated and no 
significant differences were observed (data not shown).  We hypothesized that 
mechanical strength is dependent on defect bridging.  Whereas some samples contain a 
large amount of bone in the defect site, high levels of mechanical strength are only 
present when this bone is firmly attached to both the proximal and distal end of the host 
bone.  Without full attachment, or bridging of the defect, samples that have large bone 
volumes sustain low torque loads. 
 To demonstrate that mechanical strength is dependent on defect bridging, 
Faxitron images for all samples were blindly assessed for their extent of bridging and 
assigned a bridging score from 0-5 based on the criteria outlined in Figure  5.5B, where 0 
is no bone in the defect and 5 is a fully bridged defect.  Representative Faxitron images 
for each score are shown in Figure  5.5C.  By looking at bone volume versus maximum 
torque for each sample grouped by briding scores, a trend is observed where samples 
with higher bridging scores generally have greater max torque (Figure  5.5D).  Although 
there are no significant differences in torsional strength between uncoated PCL-treated 
defects and GFOGER-treated defects, a distribution of bridging scores from each group 
shows that GFOGER scores are shifted towards fully bridged or nearly fully bridged 
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(scores 4 and 5) compared to PCL scores (Figure  5.5E).  This shift found to be significant 
by a Kruskall Wallis one way ANOVA by ranks (p < 0.05). 
Effects of GFOGER on bone formation are surface area dependent 
 We hypothesized that the effects of GFOGER on bone formation are dependent 
on the area of scaffold in direct contact with host bone because the surface area of the 
scaffold directly affect the dose of GFOGER delivered to the defect site.  Uncoated and 
GFOGER-coated PCL scaffolds with varying surface area to volume ratios were 
implanted in critically-sized segmental defects to test for surface area dependent effects 
of GFOGER.  MicroCT analysis shows that GFOGER significantly enhances bone 
formation compared to uncoated PCL scaffolds only when the surface area to volume 
ratio of the scaffolds is above 3.1 mm-1 (Figure  5.6).  In vitro ELISA detection of 
biotinylated GFOGER adsorbed at a saturating concentration of 50 µg/mL onto PCL 
scaffolds with various surface area to volume ratios shows significantly more total 




Figure  5.5.  Mechanical properties of repaired segmental defects.  (A) Despite differences in bone volume 
between GFOGER-treated defects and PCL-treated or empty defects, maximum torque is not significantly 
different.  (B) Criteria for bridging scores assigned to each sample.  (C) Representative faxitron images of 
scores described in (B).  (D) Samples with higher bridging scores are shifted to the upper right of a bone 
volume versus maximum torque correlation graph.  (E) GFOGER-coated samples result in a greater 





Figure  5.6. Effects of GFOGER are dependent on scaffold surface area to volume ratio.  (A) In vivo results 
show greater bone volume in GFOGER-treated defects compared to uncoated PCL only when the scaffold 
surface area to volume ratio is high. Bone volume is quantified by microCT at 12 weeks post-op 
(*Different from uncoated scaffolds in the same SA:Vol group, p < 0.05).  (B) Biotinylated GFOGER 
detected on the surface of PCL scaffolds with varying surface area to volumes ratios via ELISA.  Scaffolds 
with the highest surface area to volume ratio have more GFOGER than the others (§ Different from all 







 This study examined the effect of coating synthetic polymer scaffolds with a 
biomimetic peptide sequence from collagen I on the in vivo bone healing of critically-
sized defects in rats.  We found that simple surface modification by adsorption of the 
peptide, GFOGER, to the scaffold accelerated and promoted significantly more bone 
formation in segmental femoral defects treated with coated scaffolds compared to 
uncoated scaffolds.  We further demonstrated that GFOGER-mediated bone formation is 
dependent on scaffold surface area, an indication that the dose of GFOGER delivered to 
the site or the area of GFOGER in direct contact with host cells directs the host reparative 
response.  The implications of this study are significant for clinical healing of large bone 
defects because this cell and growth factor-free method for bone regeneration addresses 
many issues with current regenerative medicine technologies.  Namely, the fabrication of 
the synthetic peptide sequence, GFOGER, is inexpensive and provides a more cost 
effective method treatment method than strategies employing BMPs.  Furthermore, the 
use of synthetic materials avoids the issue of immune response to these biologically-
derived biomolecules.  This simple surface modification strategy which uses passive 
adsorption to coat biomaterials for bone regenerating scaffolds provides a simple method 
for imparting biofunctionality to synthetic surfaces, which could easily be translated to 
other materials. 
 The critical role of integrin activation in cell adhesion and signaling has been well 
established (Clark and Brugge 1995; Hynes 2002).  In particular, the specific interactions 
of fibronectin with the α5β1 integrin and of type I collagen with the α2β1 integrin have 
been shown to mediate osteoblast differentiation and subsequent mineralization of 
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osteoblastic and pre-osteoblastic cells (Moursi et al. 1997; Takeuchi et al. 1997; Xiao et 
al. 1998; Jikko et al. 1999; Mizuno et al. 2000).  Over the past decade, targeting of these 
specific ECM-integrin interactions to exert engineered control over osteoblastic function 
has been accomplished via isolation of specific binding sequences, such as RGD, from 
ECM proteins.  Successful osseointegration and implant fixation has been demonstrated 
in vivo using RGD as a biomaterial coating (Ferris et al. 1999; Bernhardt et al. 2005; 
Elmengaard et al. 2005), and these strategies often enhance osteoblastic activity to a 
greater extent than the native ECM molecules (Kurihara and Nagamune 2005).  Recently, 
work in our group has demonstrated a significant improvement in osseointegration and 
implant fixation over RGD using the fibronectin fragment, FNIII7-10, which contains a 
synergy site in addition to RGD (Petrie et al. 2008).  Although these strategies are 
promising, little work has focused on the presentation of non-RGD peptide motifs that 
target the collagen-α2β1 interaction (García and Reyes 2005). 
 Activation of the α2β1 integrin is presently known to occur via binding of distinct 
adhesive sites contained within collagen I, namely DGEA and GFOGER (Xiao et al. 
1998; Knight et al. 2000).  In studies comparing RGD to DGEA, cell adhesion strength 
was greater on surfaces presenting RGD over DGEA (Harbers and Healy 2005).  
Although several studies have characterized the effect of DGEA on other cell types, the 
role of DGEA in osteoblast signaling and differentiation is presently unclear (Marquis et 
al. 2008).  On the other hand, our group has previously reported increased osteoblastic 
differentiation on GFOGER coated surfaces in vitro, and this effect translated to 
increased osseointegration and implant fixation on GFOGER-coated titanium implants in 
vivo (Reyes and García 2003; Reyes and García 2004; Reyes et al. 2007).  In those 
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studies, the effects of GFOGER on osteoblastic differentiation and mineralization were 
greater than that for native collagen I, indicating that the GFOGER peptide has greater 
targeting specificity than full length collagen I, most likely due to the elimination of other 
binding sites (such as DGEA) present on collagen I.  Many studies have explored the use 
of collagen sponges as carriers for cells and growth factors to heal segmental orthotopic 
defects.  While collagen sponges have demonstrated good use as carriers, no significant 
effect on orthotopic bone formation has been demonstrated with empty collagen carriers 
alone (Pekkarinen et al. 2006; Chen et al. 2007; Azad et al. 2009).   To our knowledge, 
the present study is the first to examine the use of the collagen-mimetic peptide, 
GFOGER, in a critically-sized orthotopic segmental defect.  While collagen alone does 
not successfully heal critically-sized bone defects, we demonstrate a significant 
enhancement in bone formation, with complete defect bridging occurring in some cases, 
due to GFOGER coating alone, without the use of cells or growth factors.  It is likely that 
the suboptimal results obtained from uncoated scaffolds is due to non-specific adsorption 
of serum proteins to the scaffold surface, leading to non-specific signaling and an 
unregulated host cell response.  Meanwhile, GFOGER-coated scaffolds promote specific 
binding of α2β1 integrin, thereby upregulating osteogenesis in surrounding host cells.  
This signaling response may via preferential binding and recruitment of osteoprogenitor 
cells present in or around the defect site to GFOGER, or via increased differentiation of 
uncommitted cells bound to GFOGER on the scaffold or some combination thereof. 
   In the late 1990s, a 15 amino acid peptide sequence, termed P-15, was isolated 
from collagen I, and shown to exhibit collagen-mimetic cell signaling when used as a 
surface coating (Qian and Bhatnagar 1996; Bhatnagar et al. 1999).  Although P-15 
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signaling has not been specifically linked to the α2β1 integrin, use of P-15 as a coating on 
anorganic bone matrix (ABM) promotes osteoblastic differentiation and mineralization in 
vitro (Yang et al. 2004).  Preclinical studies using P-15/ABM implants in orthotopic 
defects have demonstrated successful defect healing in two different models.  Scarano et 
al. report significant healing of a monocortical tibial defect in rabbits using P-15/ABM 
(Scarano et al. 2003).  Similarly, Cakmak et al. report significant healing due to P-
15/ABM in a segmental rat radial defect (Cakmak et al. 2006).  However, in both of these 
studies, P-15/ABM was compared to empty defect controls, but uncoated ABM controls 
were not included.  Furthermore, no quantitative CT analysis of bone volume was 
performed in either of these studies, making direct comparison to the present study 
difficult.  A third pre-clinical study employing P-15/ABM did not show a significant 
enhancement in healing of a rabbit segmental femoral defect.  However, in this study, 
empty defects demonstrated complete bridging as often as P-15/ABM treated defects 
after 12 weeks, indicating that the 5 mm rabbit radial defect used in this study was not of 
a critical size (Sarahrudi et al. 2008).  Despite few reports on successful preclinical 
testing of P-15/ABM in orthotopic sites, recent clinical data has demonstrated successful 
healing in humans due to P-15/ABM implants in several case reports (Gomar et al. 2007; 
Trombelli and Farina 2008).  Although these results are promising, little effort has been 
made to test uncoated ABM compared to P-15 complexed ABM.  ABM is porous 
particulate bone mineral derived from bovine sources, which is likely to be a naturally 
osteoconductive material.  In the present study, uncoated synthetic polymeric scaffolds 
did not produce significant healing in orthotopic defects when compared to GFOGER-
coated scaffolds.  This choice of scaffold, which does not heal the defect alone, allowed 
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us to evaluate the effects of GFOGER on defect healing without contributions from the 
scaffold.  Interestingly, a recent study comparing DGEA, P-15, GFOGER, and RGD, 
showed that GFOGER produced no cell adhesion when used as an HA coating (Hennessy 
et al. 2009).  The authors attribute this surprising result to the HA substrate employed.  
Taken together, these results indicate that the effects of GFOGER may be substrate 
dependent. 
 It is well known that ligand density and clustering have a direct effect on integrin 
activation and signaling (Massia and Hubbell 1991; Maheshwari et al. 2000).  Recent 
work in our group has demonstrated that adhesion of HT1080 human fibrosarcoma cells 
to GFOGER coated surfaces is directly dependent on the surface density of GFOGER 
(Reyes et al. 2008).  In the present study, we determined the coating concentration 
necessary to produce a saturating surface density of GFOGER on PCL scaffolds (Figure 
5.3C).  This saturating concentration was used to coat all GFOGER-coated PCL scaffolds 
used for in vivo implantations.  Because coating was performed via passive adsorption of 
GFOGER onto PCL scaffold surfaces, and ligand density and clustering were not 
precisely controlled, we, therefore, assume that ligand density and clustering were 
constant between different batches of PCL. However, we observed that PCL scaffolds 
with varying surface area to volume ratios produced differential effects on bone 
formation in vivo (Figure  5.6A).  Because ligand density and clustering were not 
specifically varied in this experiment, this difference in host response to GFOGER on 
different PCL scaffolds was most likely due to a dose dependent effect of GFOGER at 
the tissue level.  With relatively few studies that characterize the 3 dimensional in vivo 
binding environment of short synthetic integrin ligands used as biomaterial coatings, 
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future work should focus on the optimization of GFOGER dosage for in vivo 
applications.  Exploring scaffold materials, architectures, and surface areas for GFOGER 
therapy is warranted. 
 Finally, a distinct advantage of this study over many reports of segmental defect 
healing is the use of mechanical testing to assess functionality of the defects.  A large 
majority of studies that report successful healing of bone defects rely solely on a 
combination of X-ray analysis and histological evaluation as a measure of defect healing.  
However, this approach does not provide functional information, which is necessary to 
fully evaluate the success of a given treatment strategy for bone healing (Liebschner 
2004).  Few groups report mechanical testing analysis, but of those that do, the most 
common test methods are torsion (Cook et al. 1994; Cook et al. 1994; Cook et al. 1995; 
Hsu et al. 2007; Oest et al. 2007; Rai et al. 2007).  In this study, we used torsional testing 
to evaluate the functional strength of the defects.  Despite differences in bone formation, 
the average torsional strength of GFOGER treated defects was not significantly different 
from that of PCL treated defects, pointing to the need for careful mechanical evaluation 
in bone tissue engineering to assess function of tissue engineered defects. However, we 
did observe differences in torsional strength between fully bridged samples compared to 
non-unions.  This result is in agreement with a mounting body of work suggesting that 
greater bone mass will not necessarily result in greater bone strength.  For example, 
recent evidence suggests that patients with a high level of bone turnover may be at higher 
risk for bone fracture regardless of areal bone mineral density (Hernandez 2008). This 
concept is known as bone quality, a term used to describe any skeletal aspect of bone, 
excluding bone mass (i.e. bone shape, size, trabecular connectivity, etc) that affects its 
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strength (Hernandez and Keaveny 2006).  In the present study, although significant 
increases in bone mass were observed due to GFOGER treatment, bone quality was not 
affected.  The implication of these results is that radiographic and histological methods of 
evaluating bone tissue are not sufficient to fully characterize the extent of bone defect 
healing.  Functional mechanical evaluation of bone defects should be used in conjunction 
with other methods for complete analysis of both bone mass and bone quality. 
 In conclusion, this simple surface modification of synthetic bone implants imparts 
biologic functionality without the use of cells or growth factors.  The advantages of this 
method include reduced cost compared to purification of natural proteins, reduced risk of 
disease transmission and reduced reliance on variability in biologics, making GFOGER 
therapy a viable treatment for future clinical bone healing. 
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 CHAPTER 6 
SUMMARY AND FUTURE CONSIDERATIONS 
 
Clinical healing of large non-unions in bone is a significant socioeconomic 
problem in the United States.  As many as 30% of patients undergoing autografts have 
been reported to suffer from donor site morbidity and pain, while approximately 30% of 
allografts fail due to fracture.  To address these issues, bone tissue engineering strategies, 
which eliminate the need for autogenous or cadaveric donor bone, present valuable 
alternatives to healing large bone defects.  In this work, two tissue engineering strategies, 
one cell-based and one biomaterials-based, were developed to promote directed 
osteoblastic differentiation for healing critically-sized defects in bone.  Although the 
approaches differed, both strategies focused on exerting control over specific signaling 
pathways involved in osteogenesis to promote bone formation.  The two strategies are 
summarized below, along with future considerations for further development of this 
research. 
Runx2 Genetic Engineering for Bone Regeneration 
In this work, we presented a cell-based strategy for bone tissue engineering, in 
which BMSCs were genetically modified to constitutively overexpress the osteoblast-
specific transcription factor, Runx2.  We demonstrated that delivery of Runx2-modified 
BMSCs to critically-sized orthotopic defects in rats accelerated the bone formation rate in 
defects at early time points compared to treatment with unmodified cells or negative 
controls.  At late time points, unmodified BMSCs eventually produced similar levels of 
bone volume, highlighting the inherent osteogenic ability of this cell type.  Recent 
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clinical work suggests that successful treatment of large bone defects in humans with 
unmodified BMSCs requires at least 5 months of external fixation of the injured limb 
post-surgery (Marcacci et al. 2007).  Therefore, a reduction in recovery time after surgery 
would add significant benefit to this treatment, making the gene therapy strategy for 
accelerated bone formation presented in the current work a valuable alternative to current 
treatments. 
Although Runx2-modified BMSCs accelerated bone formation in critically-sized 
defects compared to unmodified BMSCs, the mechanical strength of the defects after 12 
weeks was not significantly different among unmodified BMSC and Runx2-modified 
BMSC treatments.  Runx2-modified cells did result in a population shift towards fully 
bridged or nearly fully bridged defects; however, for successful healing of large bone 
defects in humans complete bridging and functional restoration of mechanical strength 
should be achieved.  To improve mechanical functionality in defects treated with Runx2-
modified cells, several parameters may be considered.  These include the therapeutic load 
of cells delivered to the defect site, scaffold type, scaffold architecture, transduction 
efficiency of the target gene, and cell type.  These parameters are briefly discussed below 
in the context of future directions for this work. 
Few studies have directly examined the effect of cell concentration on the in vivo 
osteogenic potential of bone tissue engineering constructs.  However, evidence suggests 
that an increase in the number of cells present on constructs upon implantation 
significantly increases osteogenesis (Connolly et al. 1989).  Recently, Yoshii et al. 
reported the use of a simple pressurized seeding strategy to increase cell retention and 
improve cell distribution on β-TCP scaffolds, which resulted in greater and more uniform 
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bone formation on scaffolds implanted ectopically (Yoshii et al. 2009).  Furthermore, 
previous work in our group demonstrated that Runx2-expressing dermal fibroblasts had 
significantly greater mineralization capacity in vitro on fibrous collagen sponges, which 
retained more cells upon initial seeding than PCL scaffolds with an open pore structure or 
PLGA foams (Phillips et al. 2006).  This study points to an intricate interplay between 
cell number, scaffold architecture and scaffold material.  The high surface area to volume 
ratio of a fibrous mesh in combination with the active binding sites present within 
collagen I are most likely more conducive to cell adhesion and subsequent differentiation 
than synthetic scaffolds with more open pore structures that lack adhesive sequences.  In 
the current work, a collagen mesh was incorporated into PCL scaffolds to increase cell 
retention in the void volume of the scaffolds compared to PCL scaffolds alone.  Perhaps 
the use of a fibrous collagen sponge without PCL in this model would allow greater cell 
attachment, further increasing the therapeutic load of cells delivered to the defect site, 
thereby enhancing bone healing beyond levels reported in the current work.  Another 
scaffold option is the use of naturally osteoconductive materials, such as hydroxyapatite 
or β-TCP, which promote attachment of host bone cells that will mineralize the construct 
(LeGeros 2002).  These materials have been used for bone regeneration; however, 
radiographic quantification of bone formed in the defect is difficult because these calcium 
phosphate ceramics have X-ray attenuation values very similar to bone, making image 
segmentation to isolate bone from scaffold difficult.  Alternatively, synthetic scaffolds 
presenting specific adhesive sequences, such as those investigated in Chapter 5 of this 
work, may provide an extracellular signaling environment more conducive to osteoblastic 
differentiation than unmodified synthetic scaffolds.  Because retroviral transduction of 
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primary cells is not 100% efficient, a second level of signaling presented on the scaffold, 
in addition to genetic modification of the cells, may encourage differentiation of the 
untransduced cell population delivered to the defect site.  All in all, optimization of the 
interplay between cell and scaffold parameters may enhance the bone formation and 
subsequent mechanical strength of bone defects treated with cell/scaffold constructs 
containing Runx2-modified BMSCs. 
A major contributing factor to the success of any gene therapy strategy is the type 
of gene delivery vehicle used to efficiently transduce the target cell population with the 
gene of interest.  Several gene delivery vehicles, including both viral and non-viral 
vectors and naked plasmid DNA, have been used for bone tissue engineering (Gersbach 
et al. 2007).  In the current work, Runx2 overexpression in BMSCs was achieved by 
retroviral transduction, promoting stable integration of the Runx2 transgene in 40% of the 
recipient cells.  It is possible that an increase in the transduction efficiency of Runx2 to 
donor cells would enhance the bone formation rate in critically-sized defects treated with 
Runx2-modified cells beyond levels achieved in this work.  As discussed previously in 
this dissertation, the proliferation rate and differentiation ability of BMSCs gradually 
decrease as time in culture time increases.  Because retroviral transduction only occurs in 
dividing cells, perhaps the propensity for decreased proliferation of this cell type would 
be better suited to a different vector system.  For example, lentiviral vectors promote 
stable, long-term integration of the gene of interest and effectively target non-dividing 
cells (Naldini et al. 1996).  On the other hand, alternative donor cell types or the 
elimination of the need for donor cells could be explored.  Recent work in our lab has 
demonstrated that dermal fibroblasts, a cell type less susceptible to loss of proliferation 
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than BMSCs, can be retrovirally transduced to express Runx2 with 65% transduction 
efficiency and mineralize collagen scaffolds implanted ectopically (Phillips et al. 2007).  
Perhaps the use of dermal fibroblasts in this model would allow greater Runx2 
transduction efficiency, leading to further enhancement of bone formation in critically-
sized defects.  Finally, our lab has also recently demonstrated that biomaterial-mediated 
delivery of a retroviral vector can efficiently promote transduction of target cells when 
biomaterial surface chemistry is well-controlled (Gersbach et al. 2007).  Therefore, 
implantation of a biomaterial carrier for the Runx2 retrovirus directly into a defect site 
could promote in situ transduction of host cells, thereby promoting bone formation 
without the need for donor cells.  Implementation of these gene therapy strategies may 
enhance Runx2-mediated healing of critically-sized defects in bone. 
GFOGER Surface Modification for Bone Regeneration 
In this work, we developed a biomaterials-based strategy for bone tissue 
engineering, in which synthetic PCL scaffolds were biofunctionalized with the collagen-
mimetic peptide, GFOGER.  We demonstrated that passive adsorption of GFOGER onto 
synthetic PCL scaffolds significantly increased bone formation in critically-sized 
orthotopic defects treated with GFOGER-coated scaffolds compared to defects treated 
with uncoated PCL scaffolds or empty defects.  We further demonstrated that this effect 
was dependent on scaffold surface area to volume ratio, indicating a dose dependency or 
threshold effect of GFOGER in critically-sized bone defects. This simple surface 
modification strategy imparts specific biologic functionality to synthetic surfaces, 
promoting enhanced bone healing without the use of donor cells or growth factors.  The 
implications of this study are significant for clinical healing of large bone defects because 
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this cell and growth factor-free strategy is cost-effective, evokes no immune response, 
avoids regulatory issues involving the implantation of biologic materials, and could be 
made readily available as a point of care clinical application. 
Despite differences in bone formation between GFOGER-coated and uncoated 
PCL scaffolds at 12 weeks, no significant differences in the average mechanical 
properties of defects treated with GFOGER-coated or uncoated PCL scaffolds were 
observed.  As with our cell-based approach, GFOGER-coated scaffolds resulted in a 
population shift towards fully bridged or nearly fully bridged defects compared to 
uncoated PCL scaffolds.  However, for successful healing of large bone defects in 
humans complete bridging and functional restoration of mechanical strength should be 
achieved.  To improve mechanical functionality in defects treated with GFOGER-coated 
scaffolds, several parameters may be considered.  These include the surface area to 
volume ratio of the scaffold used, scaffold architecture, scaffold material, method of 
ligand tethering, and ligand clustering.  These parameters are briefly discussed below in 
the context of future directions for this work. 
The structure of synthetic scaffolds for bone tissue engineering must meet several 
criteria in order to support bone tissue ingrowth, vascularization, and tissue remodeling.  
Importantly, scaffolds must contain a high degree of porosity, an interconnected pore 
volume, and an average pore size of at least 100 µm (Liu and Ma 2004).  In the current 
work, PCL scaffolds were created with well-controlled architectures, which provided an 
open interconnected pore volume to support bone ingrowth.  We demonstrated that the 
effects of GFOGER on bone formation in critically-sized defects depended on the surface 
area to volume ratio of the scaffold.  This surface area dependency most likely occurs 
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either because the amount of GFOGER delivered to the defect site is directly related to 
the surface area of the scaffold (i.e. scaffolds with greater surface area contain a greater 
amount of GFOGER) or because scaffolds with greater surface area have more 
opportunity for direct contact with host cells.  Thus, it is possible that the implantation of 
GFOGER-coated scaffolds with a greater surface area to volume ratio than the scaffolds 
examined in this work could result in greater bone formation than observed here.  
However, the caveat to this design change is that scaffold porosity must remain open and 
interconnected to continue to allow tissue infiltration and bone formation.  Taking 
scaffold surface area and porosity into account, synthetic scaffolds may be specifically 
designed to optimize GFOGER efficacy in vivo, thereby enhancing bone healing to levels 
beyond that of the current work. 
Finally, it is well established that ligand surface density and clustering have a 
direct effect on integrin signaling and activation (Massia and Hubbell 1991; Maheshwari 
et al. 2000).  Indeed, our group has demonstrated that cell adhesion to GFOGER coated 
surfaces is directly dependent on GFOGER surface density (Reyes and García 2003; 
Reyes et al. 2008).  In the current work, we used passive adsorption of GFOGER to 
saturate PCL scaffold surfaces.  The application of this strategy is simple, making it 
attractive for use in the clinic.  However, it is possible that well controlled deposition or 
tethering of GFOGER to specifically modulate ligand density and clustering may produce 
surfaces that are better suited for bone regeneration than those prepared by passive 
adsorption of the ligand.  Recent work in our lab has demonstrated that surface 
modification of titanium implants with non-fouling brushes that present α5β1 specific 
ligands at well-defined densities increase osseointegration and implant fixation in vivo 
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compared to unmodified titanium implants (Petrie et al. 2008).  This tethering strategy 
has also been demonstrated for GFOGER, where titanium implants, modified with well-
controlled densities of GFOGER on a non-fouling background, support cell adhesion in 
vitro (Raynor et al. 2009).  Perhaps the implementation of this strategy to generate bone 
tissue engineering scaffolds could improve the host response to GFOGER-modified 
surfaces.  Furthermore, we have observed widely varying adsorption profiles for 
GFOGER on different materials, including tissue culture polystyrene, PCL, titanium and 
glass (unpublished data), indicating that the base material used for GFOGER adsorption 
may have a significant effect on cell response to the construct.  Recently, Hennessy et al. 
found that GFOGER did not promote cell adhesion on hydroxyapatite scaffolds despite 
their own verification of GFOGER-induced cell adhesion on tissue culture polystyrene 
(Hennessy et al. 2009).  It is possible that choosing a different scaffold material or 
tethering GFOGER to materials that do not naturally adsorb GFOGER would expand the 
available options for delivery of GFOGER to critically-sized bone defects.  All in all, 
well-controlled methods for surface modification with GFOGER could more specifically 
modulate the osteogenic response of host cells to GFOGER-modified scaffolds, further 
enhancing GFOGER-mediated bone formation in critically-sized bone defects. 
Conclusions 
The work presented in this dissertation describes two strategies for bone tissue 
engineering which both target specific osteoblastic signaling pathways to promote 
enhanced healing of critically-sized bone defects.  This work is innovative because 
genetic and extracellular cues for osteoblastic differentiation are used to exert control 
over cell signaling and promote bone healing in a robust segmental defect model.  By 
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engineering BMSCs to overexpress Runx2, issues with BMSC dedifferentiation in 
culture and donor cell variability are addressed, providing a strategy for accelerated bone 
formation in large bone defects.  Furthermore, development of a cell and growth factor 
free strategy for bone regeneration via surface modification of PCL scaffolds with 
GFOGER confers biofunctionality to synthetic substrates and promotes specific signaling 
to host cells, eliminating the need for donor cells and providing a simple and elegant 
point of care strategy.  Further development of these tissue engineering strategies for 
bone regeneration will provide clinically-relevant treatment options for healing large 
bone defects in humans by eliminating the need for donor bone and employing well-
controlled signals to promote bone formation. 
References 
Connolly J, Guse R, Lippiello L and Dehne R (1989). "Development of an osteogenic 
bone-marrow preparation." J Bone Joint Surg Am 71(5): 684-91. 
Gersbach CA, Coyer SR, Le Doux JM and García AJ (2007). "Biomaterial-mediated 
retroviral gene transfer using self-assembled monolayers." Biomaterials 28(34): 
5121-7. 
Gersbach CA, Phillips JE and García AJ (2007). "Genetic engineering for skeletal 
regenerative medicine." Annu Rev Biomed Eng 9: 87-119. 
Hennessy KM, Pollot BE, Clem WC, Phipps MC, Sawyer AA, Culpepper BK and Bellis 
SL (2009). "The effect of collagen I mimetic peptides on mesenchymal stem cell 
adhesion and differentiation, and on bone formation at hydroxyapatite surfaces." 
Biomaterials 30(10): 1898-909. 
LeGeros RZ (2002). "Properties of osteoconductive biomaterials: calcium phosphates." 
Clin Orthop Relat Res(395): 81-98. 
Liu X and Ma PX (2004). "Polymeric scaffolds for bone tissue engineering." Ann 
Biomed Eng 32(3): 477-86. 
 
 128 
Maheshwari G, Brown G, Lauffenburger DA, Wells A and Griffith LG (2000). "Cell 
adhesion and motility depend on nanoscale RGD clustering." J Cell Sci 113 ( Pt 
10): 1677-86. 
Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, 
Mastrogiacomo M and Cancedda R (2007). "Stem cells associated with 
macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot 
clinical study." Tissue Eng 13(5): 947-55. 
Massia SP and Hubbell JA (1991). "An RGD spacing of 440 nm is sufficient for integrin 
alpha V beta 3-mediated fibroblast spreading and 140 nm for focal contact and 
stress fiber formation." J Cell Biol 114(5): 1089-100. 
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM and Trono D 
(1996). "In vivo gene delivery and stable transduction of nondividing cells by a 
lentiviral vector." Science 272(5259): 263-7. 
Petrie TA, Raynor JE, Reyes CD, Burns KL, Collard DM and García AJ (2008). "The 
effect of integrin-specific bioactive coatings on tissue healing and implant 
osseointegration." Biomaterials 29(19): 2849-57. 
Phillips JE, Guldberg RE and García AJ (2007). "Dermal Fibroblasts Genetically 
Modified to Express Runx2/Cbfa1 as a Mineralizing Cell Source for Bone Tissue 
Engineering." Tissue Eng 13(8). 
Phillips JE, Hutmacher DW, Guldberg RE and García AJ (2006). "Mineralization 
capacity of Runx2/Cbfa1-genetically engineered fibroblasts is scaffold 
dependent." Biomaterials 27(32): 5535-45. 
Raynor JE, Petrie TA, Fears KP, Latour RA, García AJ and Collard DM (2009). 
"Saccharide polymer brushes to control protein and cell adhesion to titanium." 
Biomacromolecules 10(4): 748-55. 
Reyes CD and García AJ (2003). "Engineering integrin-specific surfaces with a triple-
helical collagen-mimetic peptide." J Biomed Mater Res A 65(4): 511-23. 
Reyes CD, Petrie TA and García AJ (2008). "Mixed extracellular matrix ligands 




Yoshii T, Sotome S, Torigoe I, Tsuchiya A, Maehara H, Ichinose S and Shinomiya K 
(2009). "Fresh bone marrow introduction into porous scaffolds using a simple 
low-pressure loading method for effective osteogenesis in a rabbit model." J 
Orthop Res 27(1): 1-7. 
 
